日本臨牀　74/増刊6　最新冠動脈疾患学(下)

出版社： 日本臨牀社
発行日： 2016-08-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 最新冠動脈疾患学（下）―冠動脈疾患の最新治療戦略
電子書籍版： 2016-08-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

18,700 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

18,700 円(税込)

購入する

目次

  • 日本臨牀　74/増刊6　最新冠動脈疾患学（下）

    ―目次―

    特集　最新冠動脈疾患学（下）―冠動脈疾患の最新治療戦略

    9．狭心症の臨床
    10．心筋梗塞の臨床
    11．急性冠症候群の臨床（ST上昇型心筋梗塞を除く）
    12．虚血性心筋症の臨床
    13．虚血性心疾患における不整脈の臨床
    14．無症候性心筋虚血の臨床
    15．心不全の臨床
    16．川崎病の臨床
    17．特論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

IX 狭心症の臨床

P.10 掲載の参考文献
1) Heberden W : Some account of a disorder of the breast. Med Trans Coll Physicians (Lond) 2 : 59-67, 1772.
 
2) 泰江弘文 : 胸痛 (胸部不快感) 患者の診かた. 循環器病学 基礎と臨床 : 初版. 西村書店 : 641-650, 2010.
 
3) Crea F, et al : Coronary microvascular dysfunction : an update. Eur Heart J 35 : 1101-1111, 2014.
PubMed
4) Beltrame JF, et al : The Who, What, Why, When, How and Where of Vasospastic Angina. Circ J 80 : 289-298, 2016.
PubMed
P.15 掲載の参考文献
1) Campeau L : Grading of angina pectoris. Circulation 54 : 522-523, 1976.
PubMed
2) Libby P : Molecular bases of the acute coronary syndromes. Circulation 91 : 2844-2850, 1995.
PubMed
3) Pristipino C, et al : Major racial differences in coronary constrictor response between japanese and caucasians with recent myocardial infarction. Circulation 101 : 1102-1108, 2000.
PubMed
4) JCS Joint Working Group : Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J 78 : 2779-2801, 2014.
 
5) Fuster V, et al : The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 : 242-250, 1992.
PubMed
6) Farb A et al : Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93 : 1354-1363, 1996.
 
7) Cannon RO, et al : "Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 61 : 1338-1343, 1988.
PubMed
8) Kemp HG : Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms. Am J Cardiol 32 : 375-376, 1973.
PubMed
9) Suzuki H, et al : Small vessel pathology and coronary hemodynamics in patients with microvascular angina. Int J Cardiol 43 : 139-150, 1994.
PubMed
10) Suzuki H, et al : Clinical characteristics and follow-up in patients with microvascular angina. Circ J 66 : 691-695, 2002.
PubMed
11) AHA Committee Report : A reporting system on patients evaluated for coronary artery disease. Circulation 51 : 7, 1975.
 
12) Braunwald E : Unstable angina. A classification. Circulation 80 : 410-414, 1989.
PubMed
13) Anderson JL, et al : ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction : Executive summary, Circulation 116 : 803-877, 2007.
 
14) Roffi M, et al : 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Euro Heart J doi : 10. 1093/eurheartj/ehv320, 1-29, 2015.
 
P.21 掲載の参考文献
1) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. Circulation 126 : e354-e471, 2012.
PubMed
2) 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 34 : 2949-3003, 2013.
PubMed
3) De Bruyne B, et al : Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367 : 991-1001, 2012.
PubMed
4) Takano M, et al : Appearance of lipid-1aden intima and neovascularization after implantation of baremetal stents extended late-phase observation by intracoronary optical coherence tomography. J Am Coll Cardiol 55 : 26-32, 2009.
PubMed
5) Thygesen K et al : Third universal definition of myocardial infarction. J Am Con Cardiol 60 : 1581-1598, 2012.
 
6) 清野精彦 : 冠動脈疾患の進展と心筋バイオマーカー. 日本臨牀 74 (増刊4) : 327-333, 2016.
 
P.25 掲載の参考文献
1) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease.
 
2) Andersson C, et al : β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol 64 : 247-252, 2014.
 
3) 冠攣縮性狭心症の診断と治療に関するガイドライン (2013年改訂版) 日本循環器学会 2013. http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawah_h.pdf
 
4) CAPRIE Steering Committee : Arandomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 : 1329-1339, 1996.
 
5) 心筋梗塞二次予防に関するガイドライン (2011年改訂版) 日本循環器学会 2011. http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawah_h.pdf
 
6) Ishikawa Y, et al : Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circlation J 74 : 1451-1457, 2010.
 
7) 高血圧治療ガイドライン2014 (JSH2014) 日本高血圧学会高血圧ガイドライン作成委員会. http://www.jpnsh.jp/data/jsh2014/jsh2014v1_1.pdf
 
8) Action to Control Cardiovascular Risk in Diabetes Study Group, et al : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545-2559, 2008.
 
9) Zinman B, et al : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015.
PubMed
10) Hanefeld M, et al : Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients : meta-analysis of seven long-term studies. Eur Heart J 25 : 10-16, 2004.
PubMed
P.32 掲載の参考文献
1) GrUntzig A : Transluminal dilatation of coronary-artery stenosis. Lancet 331 : 263, 1978.
 
2) Sigwart U, et al : Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316 : 701-706, 1987.
PubMed
3) Schomig A, et al : A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 : 1084-1089, 1996.
PubMed
4) Morice MC, et al : A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 : 1773-1780, 2002.
PubMed
5) Serruys PW, , et al : Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 : 961-972, 2009.
PubMed
6) Davierwala P, et al : Five years after the SYNTAX trial : what have we learnt? Eur J Cardiothorac Surg 44 : 1-3, 2013.
PubMed
7) Goetz RH, et al : Internal mammary-coronary artery anastomosis. A nonsuture method employing tantalum rings. J Thorac Cardiovasc Surg 41 : 378-386, 1961.
 
8) 冠動脈外科全国アンケート調査結果2014年, 日本冠動脈外科学会. http://www.jacas.org/data/pdf/slide_2014.pdf
 
9) 水野友裕ほか : 左主幹部病変に対するOff-pump CABGを第一選択とする外科的血行再建の中長期成績. 冠疾患誌 21 : 179-184, 2015.
 
10) Horii T, et al : [The long-term patency rate of saphenous vein grafts and vein graft disease in Japanese patientsl. Nihon Kyobu Geka Gakkai Zasshi 41 : 1447-1451, 1993.
 
11) Borger MA, et al : Multiple arterial grafts. Radial versus right internal thoracic arteries. Circulation 98 : II7-13 ; discussion II13-14, 1998.
 
12) Desai ND, et al : A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med 351 : 2302-2309, 2004.
PubMed
13) Suma H, et al : Twenty years experience with the gastroepiploic artery graft for CABG. Circulation 116 : 1188-191, 2007.
 
14) Lytle BW, et al : The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. Ann Thorac Surg 78 : 2005-2012 ; discussion 2012-2014, 2004.
 
15) Taggart DP, et al : Effect of arterial revascularisation on survival : a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 358 : 870-875, 2001.
PubMed
16) Caputo M, et al : Radial versus right internal thoracic artery as a second arterial conduit for coronary surgery : early and midterm outcomes. J Thorac Cardiovasc Surg 126 : 39-47, 2003.
PubMed
P.37 掲載の参考文献
1) Nishimura T, et al : Prognostic study of risk stratification among Japanese patients With ischemic heart disease using gated myocardial perfusion SPECr : J-ACCESS study. Eur J Nucl Med Mol Imaging 35 : 319-328, 2008.
 
2) Hueb W, et al : Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS ID : a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 122 : 949-957, 2010.
PubMed
3) Boden WE, et al : Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 : 1503-1516, 2007.
 
4) Sedlis SP, et al : Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. N Engl J Med 373 : 1937-1946, 2015.
PubMed
5) Nishigaki K, et al : Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv 1 : 469-479, 2008.
PubMed
6) 安定冠動脈疾患における待機的PCIのガイドライン (2011年改訂) 」Guidelines for elective percutaneous coronary intervention in patients with stable coronary disease (JCS2011)
 
7) Authors/Task Force members, et al : 2014 ESC/EACTS Guidelines on myocardial revascularization : The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 : 2541-2619, 2014.
 
P.41 掲載の参考文献
1) Yasue H, et al : Induction of coronary artery spasm by acetylcholine in patients with variant angina : possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 74 : 955-963, 1986.
PubMed
2) Kugiyama K, et al : Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. J Am Coll Cardiol 28 : 1161-1167, 1996.
PubMed
3) Palmer RM, et al : Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 : 524-526, 1987.
PubMed
4) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 冠攣縮性狭心症の診断と治療に関するガイドライン (2013年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawah_h.pdf
 
5) Dimmeler S, et al : Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 : 601-605, 1999.
PubMed
6) Kugiyama K et al : Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 94 : 266-271, 1996.
PubMed
7) Yoshimura M, et al : A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 103 : 65-69, 1998.
 
8) Nakayama M, et al : T-786--> C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99 : 2864-2870, 1999.
PubMed
9) Miyamoto Y, et al : Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a-786T--> C mutation associated with coronary spastic angina. Hum Mol Genet 9 : 2629-2637, 2000.
PubMed
10) Nakayama M, et al : Synergistic interaction of T-786--> C polymorphism in the endothelial nitric oxide synthase gene and smoking for an enhanced risk for coronary spasm. Pharmacogenetics 13 : 683-688, 2003.
PubMed
11) Nakayama M, et al : A -786T> C polymorphism in the endothelial nitric oxide synthase gene reduces serum nitrite/nitrate levels from the heart due to an intracoronary injection of acetylcholine. Pharmacogenet Genomics 16 : 339-345, 2006.
 
12) Horowitz A, et al : Mechanisms of smooth muscle contraction. Physiol Rev 76 : 967-1003, 1996.
PubMed
13) Kimura K et al : Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) Science 273 : 245-248, 1996.
PubMed
14) Amano M, et al : Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271 : 20246-20249, 1996.
PubMed
15) Kandabashi T, et al : Evidence for protein kinase C-mediated activation of Rhekinase in a porcine model of coronary artery spasm. Arterioscler Thromb Vasc Biol 23 : 2209-2214, 2003.
 
16) Masumoto A, et al : Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil padents with vasospastic angina. Circulation 105 : 1545-1547, 2002.
 
17) 吉村道博 : 冠攣縮の病態と治療. Ther Res 26 : 1419-1426, 2005.
Medical*Online
P.46 掲載の参考文献
1) Sueda S, et al : [Survey of coronary spasm in Japan before the establishment of spasm guidelines : analysis of questionnaires throughout Japan]. J Cardiol 48 : 333-343, 2006.
PubMed
2) JCS joint working group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary spastic angina) (JCS 2013) Circ J 78 : 2779-2801, 2014.
 
3) Yasue H, et al : Induction of coronary artery spasm by acetylcholine in patients with variant angina : possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 74 : 955-963, 1986.
PubMed
4) Okumura K et al : Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. J Am Coll Cardiol 12 : 883-888, 1988.
PubMed
5) Okumura K et al : Multivessel coronary spasm in patients with variant angina : a study with intracoronary injection of acetylcholine. Circulation 77 : 535-542, 1988.
PubMed
6) Sueda S, et al : [Absence of induced spasm by intracoronary injection of 50 micrograms acetylcholine in the right coronary artery : usefulness of 80 micrograms of acetylcholine as a spasm provocation test]. J Cardiol 32 : 155-161, 1998.
 
7) Sueda S, et al : Maximal acetylcholine dose of 200 pg into the left coronary artery as a spasm provocation test : comparison with 100 pg of acetylcholine. Heart Vessels 30 : 771-778, 2015.
 
8) Sueda S, et al : Overview of the acetylcholine spasm provocation test. Clin Cardiol 38 : 430-438, 2015.
PubMed
9) Kawano H, et al : Gender difference in improvement of endothelium-dependent vasodilation after estrogen supplementation. J Am Coll Cardiol 30 : 914-919, 1997.
PubMed
10) Yasue H, et al : Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 51 : 1742-1748, 2008.
PubMed
11) Zaya M, et al : Provocative testing for coronary reactivity and spasm. J Am Coll Cardiol 63 : 103-109, 2014.
PubMed
12) Beltrame JE et al : Racial heterogeneity in coronary artery vasomotor reactivity : differences between Japanese and Caucasian patients. J Am Coll Cardiol 33 : 1442-1452, 1999.
 
13) Pristipino C, et al : Major racial differences in coronary constrictor response between japanese and caucasians with recent myocardial infarction. Circulation 101 : 1102-1108, 2000.
PubMed
14) Ong P, et al : Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation 129 : 1723-1730, 2014.
PubMed
15) Sueda S, Kohno H : Less racial difference in coronary artery spasm ; Caucasian versus Japanese. Interv Cardiol 1 : 1-5, 2015.
 
P.52 掲載の参考文献
1) Scholl JM, et al : Comparison of risk factors in vasospastic angina without significant fixed coronary narrowing to significant fixed coronary narrowing and no vasospastic angina. Am J Cardiol 57 : 199-202, 1986.
PubMed
2) Sugiishi M, et al : Cigarette smoking is a major risk factor for coronary spasm. Circulation 87 : 76-79, 1993.
 
3) Mizuno Y, et al : East asian variant of aldehyde dehydrogenase 2 is associated with coronary spastic angina : possible roles of reactive aldehydes and implications of alcohol flushing syndrome. Circulation 131 : 1665-1673, 2015.
PubMed
4) Ong P, et al : High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol 59 : 655-662, 2012.
PubMed
5) Ong P, et al : Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation 129 : 1723-1730, 2014.
PubMed
6) Tsujita K et al : Coronary plaque component in patients with vasospastic angina : a virtual histology intravascular ultrasound study. Int J Cardiol 168 : 2411-2415, 2013.
PubMed
7) Miyao Y, et al : Diffuse intimal thickening of coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 36 : 432-437, 2000.
 
8) Ozaki Y, et al : Progression and regression of coronary stenosis in the long-term follow-up of vasospastic angina. Circulation 92 : 2446-2456, 1995.
 
9) Ishii M, et al : Acetylcholine-Provoked Coronary Spasm at Site of Significant Organic Stenosis Predicts Poor Prognosis in Patients With Coronary Vasospastic Angina. J Am Coll Cardiol 66 : 1105-1115, 2015.
PubMed
10) Kaul S, et al : In search of the vulnerable plaque : is there any light at the end of the catheter? J Am Coll Cardiol 64 : 2519-2524, 2014.
PubMed
11) Wang LX, et al : Coronary spasm, a pathogenic trigger of vulnerable plaque rupture. Chin Med J 124 : 4071-4078, 2011.
PubMed
12) Oshima S, et al : Fibrinopeptide A is released into the coronary circulation after coronary spasm. Circulation 82 : 2222-2225, 1990.
PubMed
13) Misumi I, et al : Increased plasma plasminogen activator inhibitor activity after coronary spasm. Int J Cardiol 41 : 21-29, 1993.
PubMed
14) Kaikita K, et al : Soluble P-selectin is released into the coronary circulation after coronary spasm. Circulation 92 : 1726-1730, 1995.
PubMed
15) Shin ES, et al : OCT-Defined Morphological Characteristics of Coronary Artery Spasm Sites in Vasospastic Angina. JACC Cardiovasc Imaging 8 : 1059-1067, 2015.
PubMed
16) Pasupathy S, et al : Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation 131 : 861-870, 2015.
PubMed
17) Ong R et al : Coronary artery spasm as a frequent cause of acute coronary syndrome : The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol 52 : 523-527, 2008.
 
18) Nakayama N, et al : Clinical features and prognosis of patients with coronary spasm-induced non-ST-segment elevation acute coronary syndrome. J Am Heart Assoc 3 : e000795, 2014.
PubMed
19) Sato K, et al : Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm : analysis of a single-center study over 20 years. J Am Heart Assoc 2 : e000227, 2013.
PubMed
20) Takagi Y, et al : Prognostic stratification of patients with vasospastic angina : a comprehensive clinical risk score developed by the Japanese Coronary Spasm Association. J Am Coll Cardiol 62 : 1144-1153, 2013.
PubMed
P.57 掲載の参考文献
1) Ong P, et al : High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol 59 : 655-662, 2012.
PubMed
2) Ong P, et al : Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation 129 : 1723-1730, 2014.
PubMed
3) Pristipino C, et al : Major racial differences in coronary constrictor response between japanese and caucasians with recent myocardial infarction. Circulation 101 : 1102-1108, 2000.
PubMed
4) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 冠攣縮性狭心症の診断と治療に関するガイドライン (2013年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawah_h.pdf
 
5) Okumura K, et al : Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. J Am Coll Cardiol 12 : 883-888, 1988.
PubMed
6) Mizuno Y, et al : East asian variant of aldehyde dehydrogenase 2 is associated with coronary spastic angina : possible roles of reactive aldehydes and implications of alcohol flushing syndrome. Circulation 131 : 1665-1673, 2015.
PubMed
7) Ishii M, et al : Acetylcholine-Provoked Coronary Spasm at Site of Significant Organic Stenosis Predicts Poor Prognosis in Patients With Coronary Vasospastic Angina. J Am Coll Cardiol 66 : 1105-1115, 2015.
PubMed
8) Masumoto A, et al : Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105 : 1545-1547, 2002.
PubMed
9) Yasue H, et al : Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 51 : 1742-1748, 2008.
PubMed
10) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告). 不整脈の非薬物治療ガイドライン (2011年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf
 
P.62 掲載の参考文献
1) Selwyn AP, Braunwald E : Ischemic heart disease. In : Harrison's Principles of Internal Medicine (ed by Harrison) p1399-1414, McGraw Hill, USA, 2001.
 
2) Braunwald : Heart Disease, 6th ed. A textbook of cardiovascular medicine p. 1272-1353, 2001
 
3) Heberden W. Some amount of disorder of the breast. London Medical Transactions 59-67 : 1768
 
4) Silverman ME : William Heberden and Some Account of a Disorder of the Breast, Clin Cardiol 10 : 211-213, 1987.
 
5) Sampson JJ, et al : Pathophysiology and differential diagnosis of cardiac pain. Prog Cardiovasc Dis 13 : 507-531, 1971.
PubMed
6) Austen WG, et al : A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 51 : 5-40, 1975.
 
7) Gorlin R : The syndromes of cardiac pain. Major Probl Intern Med 11 : 149-172, 1976.
PubMed
8) Schlant RC, Alexander RW : Diagnosis〔and management of patients with chronic ischemic heart disease. In : Hurst's the Heart, (ed Valentine Fuster, et al), p 1275-1305, McGraw-Hill Education, USA 2001.
 
9) WHO Tech Report Series, No. 231, 1962.
 
10) Report of the joint ISFC/WHO task force on standardization of clinical nomenclature : Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 59 : 607-609, 1979.
 
11) The criteria committee of the New York Heart Association : Diseases at the Heart and Blood vessels ; No men cloture and Criteria of Diagnosis (6th ed). Little, Brown and Co., 1964.
 
12) Campeau L : Grading of angina pectoris. Circulation 54 : 522-523, 1976.
PubMed
13) Goldman L, et al : Comparative reproducibility and validity of systems for assessing cardiovascular functional class : advantages of a new specific activity scale. Circulation 64 : 1227-1234, 1981.
PubMed
14) Shub C : Angina pectoris and coronary heart disease. In : Cardiology (ed Brandenburg RO, Fuster V, et al), p1077, Year Book Med Pub inc, Chicago, 1987
 
15) International Statistical Classification of Disease and Related Health Problems, Tenth Rivision, ICD-10, World Health Organization, 1992
 
16) Campeau L : The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol 18 : 371-379, 2002.
PubMed
17) Cox J, et al : The Canadian Cardiovascular Society grading scale for angina pectoris : is it time for refinements? Ann Intern Med 117 : 677-683, 1992.
PubMed
18) 浅田次郎 : つばさよつばさ第69回「一病息災」SKY WARD 2008年11月号 p. 129-132
 
19) Braunwald E : Unstable angina. A classification. Circulation 80 : 410-414, 1989.
PubMed
20) Thygesen K et al : Third universa1 definition of myocardial infarction. Circulation 126 : 2020-2035, 2012.
PubMed
21) Rizi HR, et al : Walk-through angina phenomenon demonstrated by graded exercise radionuclide ventriculography : Possible coronary spasm mechanism. Am Heart J 103 : 292-294 : 1982.
PubMed
22) 大野晃 ほか 冠側副血行循環促進によるwalk-through現象 J Cardiol 20 : 49-53, 1990.
 
P.67 掲載の参考文献
1) Omland T et al : A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 361 : 2538-2547, 2009.
PubMed
2) Sharma K, et al : An update on exercise stress testing. Curr Probl Cardiol 37 : 177-202, 2012.
PubMed
3) Cullen MW, et al : Recent advances in stress echocardiography. Curr Opin Cardiol 26 : 379-384, 2011.
PubMed
4) Techasith T, et al : Stress myocardial CT perfusion : an update and future perspective. JACC Cardiovasc Imaging 4 : 905-916, 2011.
PubMed
5) Pijls NH, et al : Functional measurement of coronary stenosis. J Am Coll Cardiol 59 : 1045-1057, 2012.
PubMed
6) Braunwald's heart disease a textbook of cardiovascular medicine (10th ed by Mann DL, Zipes DE Libby P, Bonow RO, and Braunwald E). p1029-1041, Saunders Elsevier, 2015.
 
7) Tbnino Pへet al : Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360 : 213-224, 2009.
 
8) Bangalore S, et al : β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308 : 1340-1349, 2012.
 
9) LaRosa JC, et al : Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 : 1425-1435, 2005.
PubMed
10) Akram ON, et al : Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol 30 : 1279-1281, 2010.
PubMed
11) Wiviott SD, et al : The safety and efficacy of achieVing very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol 17 : 628-630, 2006
 
12) ONTARGET Investigators, et al : Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 : 1547-1559, 2008.
 
P.74 掲載の参考文献
1) Fihn SD, et al : 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease : a report of the American College of Cardiology Foundation/Arnerican Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 126 : e354-471, 2012.
 
2) Bucher HC, et al : Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease : meta-analysis of randomised controlled trials. BMJ 321 : 73-77, 2000.
PubMed
3) Katritsis DG, et al : Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease : a meta-analysis. Circulation 111 : 2906-2912, 2005.
PubMed
4) Stergiopoulos K et al : Initial coronary stent implantation With medical therapy vs medical therapy alone for stable coronary artery disease : meta-analysis of randomized controlled trials. Arch Intern Med 172 : 312-319, 2012.
PubMed
5) Boden WE, et al : Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 : 1503-1516, 2007.
 
6) BARI 2D Study Group, et al : A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360 : 2503-2515, 2009.
 
7) Sedlis SP, et al : Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. N Engl J Med 373 : 1937-1946, 2015.
PubMed
8) Nishigaki K, et al : Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv 1 : 469-479, 2008.
PubMed
9) De Bruyne B, et al : Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367 : 991-1001, 2012.
PubMed
10) Shaw IJ, et al : Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden : results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117 : 1283-1291, 2008.
PubMed
11) Shaw IJ, et al : Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J 164 : 243-250, 2012.
PubMed
12) Hachamovitch R, et al : Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107 : 2900-2907, 2003.
PubMed
13) Patel MR, et al : ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update : a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 59 : 857-881, 2012.
 
14) Iqbal J, et al : Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting : insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the syear follow-up. Circulation 131 : 1269-1277, 2015.
PubMed
P.79 掲載の参考文献
1) Ong P, et al : High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol 59 : 655-662, 2012.
PubMed
2) Mohri M, et al : Angina pectoris caused by coronary microvascular spasm. Lancet 351 : 1165-1169, 1998.
PubMed
3) Crea E et al : Coronary microvascular dysfunction : an update. Eur Heart J 35 : 1101-1111, 2014.
 
4) Cannon RO, et al : "Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 61 : 1338-1343, 1988.
PubMed
5) Masumoto A, et al : Threeyear follow-up of the Japanese patients with microvascular angina attributable to coronary microvascular spasm. Int J Cardiol 81 : 151-156, 2001.
PubMed
6) JCS Joint Wbrking Group : Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J 78 : 2779-2801, 2014.
PubMed
7) Pepine CJ, et al : Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's lschemia Syndrome Evaluation) study. J Am Coll Cardiol 55 : 2825-2832, 2010.
 
8) Ohba K, et al : Microvascular coronary artery spasm presents distinctive clinical featUres with endothelial dysfunction as nonobstructive coronary artery disease. J Am Heart Assoc 1 : e002485, 2012.
PubMed
9) Radico E et al : Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease : practical considerations for diagnostic tests. JACC Cardiovasc Interv 7 : 453-463, 2014.
 
10) Sun H, et al : Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol 39 : 847-851, 2002.
PubMed
11) Task Force Members, et al : 2013 ESC guidelines on the management of stable coronary artery disease : the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34 : 2949-3003, 2013.
 
12) Ong P, et al : Pharmacotherapy for coronary microvascular dysfunction. Eur Heart J Cardiovasc Pharmac 1 : 65-71, 2015.
 
13) Pauly DE et al : In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function : A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 162 : 678-684, 2011.
 
14) Kayikcioglu M, et al : Benefits of statin treatment in cardiac syndrome-X1. Eur Heart J 24 : 1999-2005, 2003.
PubMed
15) Fukumoto Y, et al : Anti-ischemic effects of fasudil, a specific Rhokmase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol 49 : 117-121, 2007.
 

X 心筋梗塞の臨床

P.87 掲載の参考文献
1) Hata J, et al : Secular trends in cardiovascular disease and its risk factors in Japanese : half-century data from the Hisayama Study (1961-2009). Circulation 128 : 1198-1205, 2013.
PubMed
2) Rumana N, et al : Trend of increase in the incidence of acute myocardial infarction in a Japanese population : Takashima AMI Registry, 1990-2001. Am J Epidemiol 167 : 1358-1364, 2008.
 
3) Tanabe N, et al : Event rates of acute myocardial infarction and coronary deaths in Niigata and Nagaoka cities in Japan. Circ J 67 : 40-45, 2003.
PubMed
4) 日本循環器学会, 循環器疾患診療実態調査. http://www.j-circ.or.jp/jittai_chosa/
 
5) Ueshima H : Explanation for the Japanese paradox : prevention of increase in coronary heart disease and reduction in stroke. J Atheroscler Thromb 14 : 278-286, 2007.
PubMed
6) Ueshima H, et al : Cardiovascular disease and risk factors in Asia : aselected review. Circulation 118 : 2702-2709, 2008.
 
7) Abbott RD, et al : Coronary artery calcification in Japanese men in Japan and Hawaii. Am J Epidemiol 166 : 1280-1287, 2007.
PubMed
8) Sekikawa A, et al : Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men : across-sectional study. J Am Coll Cardiol 52 : 417-424, 2008.
 
9) Takii T, et al : Trends in acute myocardial infarction incidence and mortality over 30 years in Japan : report from the MIYAGI-AMI Registry Study. Circ J 74 : 93-100, 2010.
PubMed
10) Yeh RW, et al : Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362 : 2155-2165, 2010.
PubMed
11) Daida H, et al : Management and two-year long-term clinical outcome of acute coronary syndrome in Japan : prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry Circ J 77 : 934-943, 2013.
PubMed
P.91 掲載の参考文献
1) Thygesen K et al : 'IEhird universal definition of myocardial infarction. Circulation 126 : 2020-2035, 2012.
PubMed
2) Libby P : Molecular bases of the acute coronary syndromes. Circulation 91 : 2844-2850, 1995.
PubMed
3) Schaar JA et al : Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 25 : 1077-1082, 2004.
PubMed
4) 泰江弘文 : 急性冠症候群 基礎から臨床まで : 冠動脈疾患の病態解明と急性冠症候群. 最新医学 54 : 1165-1171, 1999.
 
5) Fuster V, et al : The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 : 242-250, 1992.
PubMed
6) Libby P, et al : Inflammation and atherosclerosis. Circulation 105 : 1135-1143, 2002.
PubMed
7) Naruko T, et al : Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106 : 2894-2900, 2002.
PubMed
8) Yamagishi M, et al : Morphology of vulnerable coronary plaque : insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 35 : 106-111, 2000.
PubMed
9) Ino Y, et al : Difference of culprit lesion morphologies between ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome : an optical coherence tomography study. JACC Cardiovasc Interv 4 : 76-82, 2011.
PubMed
10) Ueda Y, et al : Color of culprit lesion at 6 months after plain old balloon angioplasty versus stenting in patients with acute myocardial infarction. Am Heart J 148 : 842-846, 2004.
PubMed
11) Pfeffer MA, et al : Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319 : 80-86, 1988.
PubMed
P.96 掲載の参考文献
1) 循環器病の診断の治療に関するガイドライン. ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
2) Ishihara M, et al : Thirty years trend in acute myocardial infarction during coronary angiography at a tertiary emergency center in Japan. J Cardiol 59 : 243-248, 2012.
 
3) Nallamothu BK, et al : Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction : is timing (almost) everything? Am J Cardiol 92 : 824-826, 2003.
PubMed
4) Zimetbaum PJ, et al : Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 348 : 933-940, 2003.
PubMed
5) Berger PB, et al : Inferior myocardial infarction. High-risk subgroups. Circulation 81 : 401-411, 1990.
PubMed
6) Yamaji H, et al : Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography. ST segment elevation in lead aVR with less ST segment elevation in lead V (1). J Am Coll Cardiol 38 : 1348-1354, 2001.
PubMed
7) Ishihara M, et al : Clinical Presentation, Management and Outcome of Japanese Patients With Acute Myocardial Infarction in the Troponin Era-Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET)-. Circ J 79 : 1255-1262, 2015.
PubMed
8) Roffi M, et al : 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37 : 267-315, 2016.
 
9) Autore C, et al : Role of echocardiography in acute chest pain syndrome. Am J Cardiol 86 : 41G-42G, 2000.
PubMed
10) Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), et al : ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33 : 2569-2619, 2012.
 
P.102 掲載の参考文献
1) 野々木宏, ほか : 第5章急性冠症候群 (ACS). JRC蘇生ガイドライン 2015 (日本蘇生協議会監修), p291-344, 医学書院, 2016.
 
2) Welsford M, et al : Part 5 : Acute Coronary Syndromes : 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 132 (Suppl 1) : S146-S176, 2015.
 
3) Ornato Jp : The ST-segment-elevation myocardial infarction chain of survival. Circulation 116 : 6-9, 2007.
PubMed
4) Stub D, et al : Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction. Circulation 131 : 2143-2150, 2015.
 
5) 相引眞幸, ほか : 第2章 成人の二次救命処置 (ALS). JRC蘇生ガイドライン 2015 (日本蘇生協議会監修), p43-174, 医学書院, 2016.
 
P.109 掲載の参考文献
一般社団法人日本蘇生協議会「JRC蘇生ガイドライン 2015」
 
P.112 掲載の参考文献
1) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告), ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
2) 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告), 心筋梗塞二次予防に関するガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawah_h.pdf
 
3) Pfeffer MA, et al : Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81 : 1161-1172, 1990.
PubMed
4) Mizuno Y, et al : Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction. J Card Fail 3 : 287-293, 1997.
PubMed
5) Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction : ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 2 : 57-66, 1986.
 
6) A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247 : 1707-1714, 1982.
PubMed
7) Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 : 801-807, 1981.
PubMed
8) The beta-blocker heart attack trial. beta-Blocker Heart Attack Study Group. JAMA 246 : 2073-2074, 1981.
 
9) Freemantle N, et al : beta Blockade after myocardial infarction : systematic review and meta regression analysis. BMJ 318 : 1730-1737, 1999.
PubMed
10) Roberts R, et al : Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83 : 422-437, 1991.
 
11) Konishi M, et al : Additive effects of B-blockers on renin-angiotensin system inhibitors for patients after acute myocardial infarction treated with primary coronary revascularization. Circ J 75 : 1982-1991, 2011.
 
12) Kernis SJ, et al : Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 43 : 1773-1779, 2004.
PubMed
13) Halkin A, et al : Impact of intravenous beta-blockade before primary angioplasty on surVival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 43 : 1780-1787, 2004.
PubMed
14) Hawkins NM, et al : Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease : a randomized controlled trial. Eur J Heart Fail 11 : 684-690, 2009.
PubMed
15) Jabbour A et al : Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease : a randomized crossover trial. J Am Coll Cardiol 55 : 1780-1787, 2010.
PubMed
P.117 掲載の参考文献
1) Patti G, et al : Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention : a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 123 : 1622-1632, 2011.
PubMed
2) Kim JS, et al : Efficacy of High-Dose Atorvastatin Loading Befdre Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. The STATIN STEMI Trial. JACC Cardiovasc Interv 3 : 332-339, 2010.
 
3) Post S, et al : Early statin treatment prior to primary PCI for acute myocardial infarction : REPERATOR, a randomized placebo-controlled pilot trial. Catheter Cardiovasc Interv 80 : 756-765, 2012.
PubMed
4) Kenaan M, et al : Preprocedural statin use in patients undergoing percutaneous coronary intervention. Am Heart J 168 : 110-116. e3, 2014.
 
5) Leoncini M, et al : Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome : Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 63 : 71-79, 2014.
 
6) Xinwei J, et al : Comparison of usefUlness of simvastatin 20 mg versus 80 mg in preventing contrastinduced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 104 : 519-524, 2009.
PubMed
7) Hong YJ, et al : Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 95 : 619-622, 2005.
PubMed
8) Nissen SE, et al : Effect of very high-intensity statin therapy on regression of coronary atherosclerosis : the ASTEROID trial. JAMA 295 : 1556-1565, 2006.
 
9) Takayama T, et al : Effect of rosuvastatin on coronary atheroma in stable coronary artery disease : multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 73 : 2110-2117, 2009.
PubMed
10) Okazaki S, et al : Early statin treatment in patients with acute coronary syndrome : demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event : the ESTABLISH Study. Circulation 110 : 1061-1068, 2004.
PubMed
11) Sakamoto T, et al : Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97 : 1165-1171, 2006.
PubMed
12) Cannon CE et al : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372 : 2387-2397, 2015.
 
P.123 掲載の参考文献
1) Rentrop KP, et al : Acute myocardial infarction : intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 2 : 354-363, 1979.
PubMed
2) Gruppo Italiano per Studio della Streptochinasenella Infarto Mioc-ardico (GISSI) : Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet i : 397-402, 1986.
 
3) 日本循環器学会学術委員会ガイドライン : ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
4) Keeley EC, et al : Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials. Lancet 361 : 13-20, 2003.
PubMed
5) 急性心筋梗塞によるE6010 (t-PA誘導体) の単回静注法の至適用量に関する検討-多施設二重盲検比較による後期第II相試験-. 薬理と臨床 22 : 3925-3950, 1994.
 
6) Sabatine M, et al : Additio of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 : 1179-1189, 2006.
 
7) Pinto DS, et al : Hospital delays in reperfusion for ST-elevation myocardial infarction : implications when selecting a reperfusion strategy. Circulation 114 : 2019-2025, 2006.
PubMed
8) Steg PG, et al : Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty : data from the CAPTIM randomized clinical trial. Circulation 108 : 2851-2856, 2003.
PubMed
9) Wong CK et al : Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy : an analysis from HERO-2. Lancet 367 : 2061-2067, 2006.
PubMed
10) White HD : Systems of care : need for hub-and-spoke systems for both primary and systematic percutaneous coronary intervention after fibrinolysis. Circulation 118 : 219-222, 2008.
PubMed
11) Carver A et al : Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. J Am Coll Cardiol 54 : 118-126, 2009.
 
12) Ellis SG, et al : Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358 : 2205-2217, 2008.
PubMed
13) Fernandez-Avi16s E et al : Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation : the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J 28 : 949-960, 2007.
 
14) Armstrong PW, et al : Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 368 : 1379-1387, 2013.
 
P.129 掲載の参考文献
1) Grines CL, et al : Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 341 : 1949-1956, 1999.
 
2) Antoniucci D, et al : A clinical trial comparing primary stenting of the infarct-related artery With optimal primary angioplasty for acute myocardial infarction : results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 31 : 1234-1239, 1998.
 
3) Bertrand ME, et al : Doubleblind study of the safety of clopidogrel With and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperadve study (CLASSICS). Circuladon 102 : 624-629, 2000.
PubMed
4) Isshiki T, et al : Prasllgrel, a third-generation P2Y12 receptor antagonist, in pa6ents with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J 78 : 2926-2934, 2014.
PubMed
5) Saito S, et al : Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome : the PRASFIT, ACS study. Circ J 78 : 1684-1692, 2014.
PubMed
6) Wallentin L, et al : Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 : 1045-1057, 2009.
PubMed
7) Piccolo R, et al : Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction : a meta-analysis of randomized trials. Atherosclerosis 217 : 149-157, 2011.
PubMed
8) Sabate M, et al : Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-met al stents (EXAMINATION) : 5-year results of a randomised trial. 正ancet 387 : 357-366, 2016.
 
9) Diletti R, et al : Everolimus-eluting bioresorbable vascular scaffblds for treatment of patients presenting with ST-segment elevation myocardial infarction : BVS STEMI first study. Eur Heart J 35 : 777-786, 2014.
PubMed
10) Kocka V, et al : Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction : a prospective multicentre study 'Prague 19'. Eur Heart J 35 : 787-794, 2014.
 
11) Stone GW, et al : Intracoronary abcbdmab and aspiration thrombectomy in patients with large anterior myocardial infarction : the INFUSE-AMI randornized trial. JAMA 307 : 1817-1826, 2012.
PubMed
12) Bavry AA, et al : Role of adjunctive thrombectomy and embolic protection deVices in acute myocardial infarction : acomprehensive meta-analysis of randomized trials. Eur Heart J 29 : 2989-3001, 2008.
 
13) Marzilh M, et al : Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101 : 2154-2159, 2000.
 
14) Kimura K, et al : Randomized controlled trial of TY-51924, a novel hydrophilic NHE inhibitor, in acute myocardial infarction. J Cardiol 67 : 307-313, 2016.
PubMed
15) Iwakura K, et al : Nicorandil treatment in patients with acute myocardial infarction : a meta-analysis. Circ J 73 : 925-931, 2009.
PubMed
P.135 掲載の参考文献
1) Fuster V, et al : The pathogenesls of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 : 242-250, 1992.
PubMed
2) Prasad A et al : Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients : an analysis from the CADILLAC trial. Am Heart J 147 : 669-675, 2004.
PubMed
3) Morishima I, et al : Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 36 : 1202-1209, 2000.
PubMed
4) Henriques JE et al : Incidence and clinical sign姐cance of distal emboUzation during primary angioplasty for acute myocardial infarction. Eur Heart J 23 : 1112-1117, 2002.
 
5) Saber RS, et al : Coronary embolization after balloon angioplasty or thrombolytic therapy : an autopsy study of 32 cases. J Anl Coll Cardiol 22 : 1283-1288, 1993.
PubMed
6) Levine GN, et al : 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction : An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Intervendons. Circulation 15 : 1135-1147, 2016.
 
7) Ikari Y, et al : Upfront thrombus aspiration in primary coronary intervention for patients with ST-segment elevation acute myocardial infarction : report of the VAMPIRE (VAcuuM asPIration thrombus REmoval) trial. JACC Cardiovasc Interv 1 : 424-431, 2008.
PubMed
8) Svilaas T et al : Thrombus aspiration during Primary percutaneous coronary intervention. N Engl J Med 358 : 557-567, 2008.
PubMed
9) Vlaar PJ, et al : Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (rAPAS) : a1-year follow-up study. Lancet 371 : 1915-1920, 2008.
 
10) Frobert O, et al : thrombus aspiration during STLsegment elevation myocardial infarction. N Engl J Med 369 : 1587-1597, 2013.
PubMed
11) Lagerqvist B, et al : Outcomes 1 year after thrombus aspiradon for myocardial infarcdon. N Engl J Med 371 : 1111-1120, 2014.
PubMed
12) Jolly SS, et al : RandomiZed trial of primary PCI with or without routine manual thrombectomy. N Engl J Med 372 : 1389-1398, 2015.
 
13) Jolly SS, et al : Outcomes after thrombus aspiration for ST elevation myocardial infarction : 1-year follow-up of the prospective randomised TOTAL trial. Lancet 387 : 127-135, 2016.
PubMed
14) Jolly SS, et al : Stroke in the TOTAL trial : a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. Eur Heart J 36 : 2364-2372, 2015.
 
P.139 掲載の参考文献
1) Takii T, et al : Trends in acute myocardial infarction incidence and mortality over 30 years in Japan : report from the MIYAGI-AMI Registry Study. Circ J 74 : 93-100, 2010.
PubMed
2) Nishida T, et al : Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation 110 : 3055-3061, 2004.
PubMed
3) Fukumoto Y, et al : Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis 17 : 63-70, 2006.
PubMed
4) Kikuchi Y, et al : Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J 74 : 589-591, 2010.
PubMed
5) Ito K et al : Extracorporeal shock wave therapy as a new and non-invasive angiogenic strategy. Tohoku J Exp Med 219 : 1-9, 2009.
PubMed
6) 伊藤健太, 下川宏明 : 体外衝撃波を用いた非侵襲性血管新生治療. 日内会誌 99 : 2846-2852, 2010.
 
7) Ito K, et al : Extracorporeal shock wave therapy for ischemic cardiovascular disorders. Am J Cardiovasc Drugs 11 : 295-302, 2011.
PubMed
8) Uwatoku T, et al : Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs. Coron Artery Dis 18 : 397-404, 2007.
PubMed
9) Ito Y, et al : Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo. Coron Artery Dis 21 : 304-311, 2010.
PubMed
10) Abe Y, et al : Extracorporeal low-energy shock-wave therapy exerts anti-inflammatory effects in a rat model of acute myocardial infarction. Circ J 78 : 2915-2925, 2014.
 
11) Serizawa F, et al : Extracorporeal shock wave therapy improves the walking ability of patients with peripheral artery disease and intermittent claudication. Circ J 76 : 1486-1493, 2012.
PubMed
12) Hayashi D, et al : Low-energy extracorporeal shock wave therapy enhances skin wound healing in diabetic mice : a critical role of endothelial nitric oxide synthase : Wound Repair Regen 20 : 887-895, 2012.
PubMed
13) Yamaya S, et al : Low-energy extracorporeal shock wave therapy promotes vascular endothelial growth factor expression and improves locomotor recovery after spinal cord injury. J Neurosurg 121 : 1514-1525, 2014.
PubMed
14) Serizawa F, et al : Extracorporeal shock wave therapy induces therapeutic lymphangiogenesis in a rat model of secondary lymphoedema. Eur J Vasc Endovasc Surg 42 : 254-260, 2011.
 
15) Saito S, et al : Extracorporeal Shock Wave Therapy for Digital Ulcers of Systemic Sclerosis : A Phase 2 Pilot Study. Tohoku J Exp Med 238 : 39-47, 2016.
PubMed
P.144 掲載の参考文献
1) Saltin B, et al : Response to exercise after bed rest and after training. Circulation 38 (5 Suppl) : VII1-78, 1968.
 
2) Long-term effects of intravenous thrombolysis in acute myocardial infarction : final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nelrlnfarto Miocardico (GISSI). Lancet 2 : 871-874, 1987.
PubMed
3) GISSI-2 : a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 336 : 65-71, 1990.
PubMed
4) Stone GW, et al : Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era : the Primary Angioplasty in Myocardial lnfarction (PAMI) trail. J Am Coll Cardiol 25 : 370-377, 1995.
 
5) Dorn J, et al : Results of a multicenter randomized clinical trial of exercise and long-term survival in myocardial infarction patients : the National Exercise and Heart Disease Project (NEHDP). Circulation 100 : 1764-1769, 1999.
 
P.148 掲載の参考文献
1) Solomon SD, et al : Sudden death in patients With myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352 : 2581-2588, 2005.
 
2) Pell S, Fayerweather WE. Trends in the incidence of myocardial infarction and in associated mortality and morbidity in a large employed population, 1957-1983. N Engl J Med 54 : 477-486, 2009.
 
3) Furman MI, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non- Q-wave myocardial infarction : a multi-hospital, community-wide perspective. J Am Coll Cardiol 37 : 1571-80, 2001.
PubMed
4) Newby KH, et al : Sustained ventricular arrhythmias in patients receiving thrombolytic therapy : incidence and outcomes. The GUSTO Investigators. Circulation 98 : 2567-2573, 1998.
PubMed
5) Mehta RH, et al : Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA 301 : 1779-1789, 2009.
 
6) Goyal A et al : Serum potassium levels and mortality in acute myocardial infarction. JAMA 307 : 157-164, 2012.
PubMed
7) Volpi A et al : Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction-results of the Gruppo Italiano per lo Studio della Soprawivenza nelrInfarto Miocardico (GISSI-2) database. Am J Cardiol 82 : 265-271, 1998.
PubMed
8) Gheeraert PJ, et al : Risk factors for primary ventricular fibrillation during acute myocardial infarction : asystematic review and meta-analysis. Eur Heart J 27 : 2499-2510, 2006.
 
9) Naruse Y, et al : Early repolarization is an independent predictor of occurrences of ventricular fibrillation in the very early phase of acute myocardial infarction. Circ Arrhythm Electrophysiol 5 : 506-513, 2012.
PubMed
10) Neuman RW, et al. Part 8 : adult advanced cardiovascular lire support : 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122 : S729-767, 2010.
 
11) Jensen GV, et al : Does in-hospital ventricular fibrillation affect prognosis after myocardial infarction? Eur Heart J 18 : 919-924, 1997.
PubMed
12) Yusu S, et al : Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. Circ J 73 : 2021-2028, 2009.
PubMed
13) Teo KK, et al : Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270 : 1589-1595, 1993.
PubMed
14) Jons C, et al : The incidence and prognostic significance of new-onset aUial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction : a CARISMA substudy. Heart Rhythm 8 : 342-348, 2011.
PubMed
P.153 掲載の参考文献
1) Dressler W : The post myocardial syndrome. Arch Intern Med 103 : 28-42, 1959.
PubMed
2) Webb GD, et al : Disease of the heart, pericardium, and pulmonary vasculature bed. In : Brawnwald's Heart Disease, eight edition (ed by Libby P, et al), p 1849-1850, Saunders Elsevier, Philadelphia, 2007.
 
3) 福井次矢, ほか : 心膜疾患 : ハリソン内科学, 第3版 (原著第17版), 232 : 1552-1559.
 
4) Axel L : Assessment of pericardial disease by magnetic resonance and computed tomography. J Magn Reson Imaging 19 : 816-826, 2004.
 
5) Van Kolen K, et al : Fever after acute myocardial infarction : Dressler's syndrome demonstrated on cardiac MRI. Int J Cardiol 183 : 209-210, 2015.
 
6) Hoit BD : Management of effusive and constrictive pericardial heart disease. Circulation 105 : 2939-2942, 2002.
PubMed
7) Reinecke H, et al : Left ventricular pseudoaneurysm in a patient with Dressler's syndrome after myocardial infarction. Heart 80 : 98-100, 1998.
 
8) Kibos A et al : Postcardiac injury syndrome complicating radiofrequenCy ablation of the atrioventricular node. Acute Card Care 8 : 122-124, 2006.
PubMed
9) 南健太郎 : 心筋梗塞後症候群 (Dressler症候群). 日本臨牀 35 : 856-859, 2016.
 
10) Porter G, et al : Dressler's syndrome post-pacemaker insertion. Br J Hosp Med (Lond) 69 : 294, 2008.
 
11) Lichstein E, et al : Current incidence of postmyocardial infarction (Dressler's) syndrome. Am J Cardiol 50 : 1269-1271, 1982.
 
12) van der Geld H : Anti-heart antibodies in the postpericardiotomy and the postmyocardial-infarction syndromes. Lancet 2 : 617-621, 1964.
PubMed
13) Luckie M, et al : Dressler's syndrome following pulmonary vein isolation for atrial fibrillation. Acute Card Care 10 : 234-235, 2008.
 
14) Maisch B, Nstic AD : Practical aspects of the management of pericardial disease. Heart 89 : 1096-1103, 2003.
 
P.160 掲載の参考文献
1) Pollak H, et al : Frequency of left ventricular free wall rupture complicating acute myocardial infarction since the advent of thrombolysis. Am J Cardiol 74 : 184-186, 1994.
PubMed
2) Becker RC, et al : Fatal cardiac ruptUre among patients treated with thrombolytic agents and adjunctive thrombin antagonists : observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol 33 : 479-487, 1999.
PubMed
3) Roberts WC, et al : Commonalities of cardiac rupture (left ventricular free wall or ventricular septum or papillary muscle) during acute myocardial infarction secondary to atherosclerotic coronary artery disease. Am J Cardiol 115 : 125-140, 2015.
 
4) Lillehei CW, et al : Surgical management of myocardial infarction. Circulation 39 (Suppl IV) : 315-339, 1969.
 
5) Padro JM, et al : Subacute cardiac rupture : repair with a sutureless technique. Ann Thorac Surg 55 : 20-23 ; discussion 23-24, 1993.
 
6) Cooley DA, et al : Surgical repair of ruptured interventricular septum following acute myocardial infarction. Surgery 41 : 930-937, 1957.
PubMed
7) Daggett WM, et al : Surgery for post-myocardial infarct ventricular septal defect. Ann Surg 186 : 260-271, 1977.
PubMed
8) David TE, et al : Postinfarction ventricular septal rupture : repair by endocardial patch with infarct exclusion. J Thorac Cardiovasc Surg 110 : 1315-1322, 1995.
PubMed
9) David TE, et al : Surgical repair of postinfarction ventricular septal defect by infarct exclusion. Semin Thorac Cardiovasc Surg 10 : 105-110, 1998.
PubMed
10) Isoda S, et al : "Sandwich Technique" via a Right Ventricle Incision to Repair PostinfarcUon Ventricular Septal Defects. J Card Surg 30 : 488-493, 2015.
 
11) Merat FV : Observations sur une lesion organique du coeur par rupture d'une des colonnes charnues du ventricule gauche. J Med Chir Pharmacol Paris 6 : 587-600, 1803.
 
12) Austen WG, et al : Ruptured papillary muscle. Report of a case with successfUl mitral valve replacement. Circulation 32 : 597-601, 1965.
PubMed
13) 鈴木伸一, ほか : 急性心筋梗塞後の後乳頭筋完全断裂による僧帽弁閉鎖不全症の1手術例. 日胸外会誌 41 : 266-272, 1993.
 
14) Bouma W, et al : Mitral valve repair for post-myocardial infarction papillary muscle rupture. Eur J Cardio-Thoracic Surg 44 : 1063-1069, 2013.
 
15) Bilge M, et al : Successful percutaneous mitral valve repair with the MitraClip system of acute mitral regurgitation due to papillary muscle rupture as complication of acute myocardial infarction. Catheter Cardiovasc Interv 83 : E137-140, 2014.
PubMed
P.165 掲載の参考文献
1) French BA, et al : Mechanisms of Post-lnfarct Left Vennicular Remodeling. Drug Discov Today Dis Mech 4 : 185-196, 2007.
PubMed
2) Konstam MA, et al : Left ventricular remodeling in heart failure : current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 4 : 98-108, 2011.
PubMed
3) Zouggari Y, et al : B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med 19 : 1273-1280, 2013.
 
4) Boon RA, et al : MicroRNA-34a regtilates cardiac ageing and function. Nature 495 : 107-110, 2013.
PubMed
5) Ter Horst EN, et al : Modulators of Macrophage Polarization Influence Healing of the Infarcted Myocardium. Int J Mol Sci 16 : 29583-29591, 2015.
PubMed
P.170 掲載の参考文献
1) Lamas GA, et al : Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. Circulation 92 : 1101-1109, 1995.
PubMed
2) Heffer MA et al : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 : 669-677, 1992.
 
3) Kober L, et al : A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 : 1670-1676, 1995.
 
4) Heffer MA, et al : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 : 1893-1906, 2003.
 
5) 心筋梗塞2次予防に関するガイドライン (2006年改訂版)
 
6) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
7) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
8) ST上昇型急性心筋梗塞の診療に関するガイドライン2013年度改訂版
 
9) Doughty RN, et al : Effects of carvedilol on left ventricular remodeling after acute myocardial infarction. Circulation 109 : 201-206, 2004.
PubMed
10) Groenning BA, et al : Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 36 : 2072-2080, 2000.
PubMed
11) Prichard BNC. The second Lilly Prize Lecture, University of Newcastle, July 1977. β-adrenergic receptor blockade in hypertension, past, present and fUture. Br J Clin Pharmacol 5 : 379-399, 1978.
 
12) Freemantle N, et al : beta Blockade after myocardial infarction : systematic review and meta regression analysis. BMJ 318 : 1730-1737, 1999.
PubMed
13) Jason J, et al : Left ventricular remodeling in the post-infarction heart : a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev 16 : 13-21, 2011.
 
P.175 掲載の参考文献
1) Maddox TM, et al : Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices : insights from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 63 : 539-546, 2014.
PubMed
2) Iqbal J, et al : Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting : insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the syear foIlow-up. Circulation 131 : 1269-1277, 2015.
PubMed
3) 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告), 心筋梗塞二次予防に関するガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawah_h.pdf
 
4) Feres E et al : Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents : the OPTIMIZE randomized trial. JAMA 310 : 2510-2522, 2013.
 
5) Mauri L, et al : Twelve or 30 months of dual an6platelet therapy after drug-eluting stents. N Engl J Med 371 : 2155-2166, 2014.
 
6) Navarese EB et al : Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents : meta-analysis of randomised controlled trials. BMJ 350 : h1618, 2015.
 
7) McMurray J, et al : Antiarrhythmic effect of carvedilol after acute myocardial infarction : results of the Carvedilol Post-lniiarct Survival Control in Left Vennicular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 : 525-530, 2005.
 
8) Dargie HJ : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet 357 : 1385-1390, 2001.
PubMed
9) Cannon CB et al : Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 : 1495-1504, 2004.
 
10) Okazaki S, et al : Early statin treatment in patients with acute coronary syndrome : demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event : the ESTABLISH Study. Circulation 110 : 1061-1068, 2004.
PubMed
11) Cannon CP, et al : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372 : 2387-2397, 2015.
PubMed
12) Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMD Investigators : Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93 : 969-973, 2004.
PubMed
13) Yui Y, et al : Comparison of nifedipine retard With angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease : the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 27 : 181-191, 2004.
PubMed
14) Blood Pressure Lowering Treatment Trialists' Collaboration, et al : Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25 : 951-958, 2007.
PubMed
15) Pitt B, et al : Eplerenone, a selec6ve aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
P.181 掲載の参考文献
1) 日本冠動脈外科学会 (http://www.jacas.org/) アンケート結果から
 
2) Mohr FW, et al : Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease : 5year follow-up of the randomised, clinical SYNTAX trial. Lancet 381 : 629-638, 2013.
PubMed
3) Farkouh, et al : for the FREEDOM Trial investigators : Strategies for multivessel revascularization in patients with diabetes. N Eng J Med 367 : 2375-2384, 2012.
 
4) Kolh P, et al : 2014 ESC/EACTS Guidelines on myocardial revascularization : the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCD. Eur J Cardiothorac Surg 46 : 517-592, 2014.
 
5) Lytle BW, et al : Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg 117 : 855-872, 1999.
 
6) Buxton BE et al : Radial artery patency and clinical outcomes : five-year interim results of a randomized trial. J Thorac Cardiovasc Surg 125 : 1363-1371, 2003.
 
7) Shi WY, et al : Is the radial artery associated with improved survival in older patients undergoing coronary artery bypass grafting? An analysis of a multicentre experience. Eur J Cardiothorac Surg 49 : 196-202, 2016.
PubMed
8) Nishigawa K, et al : V-composite grafting using the right interal thoracic artery grafts anastomosed to aorto-coronary bypass graft. Eur J Cardiothorac Surg 48 : 753-202, 2016.
 
9) Takanashi S, et al : 0ff-pump long onlay bypass grafting using left internal mammary artery for diffusely diseased coronary artery. Ann Thorac Surg 76 : 635-637, 2003.
 
10) Nishigawa K, et al : Ten-year experience of off-pump coronary endarterectomy for the diffusely diseased left anterior descending ar tery. Innovations 10 : S61, 2015.
 
11) Coleman WS, et al : Surgical intervention in acute myocardial infarction : an historical perspective. Semin Thorac Cardiovasc Surg 7 : 176-183, 1995.
PubMed
12) Kerendi E et al : Emergency coronary artery bypass grafting can be performed safely without cardiopulmonary bypass in selected patients. Ann Thorac Surg 79 : 801-806, 2005.
 
13) 福井寿啓, ほか : 急性心筋梗塞に対するOPCABの成績. 胸部外科 62 : 36-40, 2009.
 
P.187 掲載の参考文献
1) Takahashi K, et al : Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 : 861-872, 2007.
PubMed
2) Ieda M, et al : Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142 : 375-386, 2010.
PubMed
3) Davis RL, et al : Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51 : 987-1000, 1987.
PubMed
4) Song K, et al : Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485 : 599-604, 2012.
PubMed
5) Inagawa K, et al : Induction of cardiomyocyte-like cells in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. Circ Res 111 : 1147-1156, 2012.
PubMed
6) Wang L, et al : Stoichiometry of Gata4, Mel2c, and Tbx5 influences the efficiency and quality of induced cardiac myocyte reprogramming. Circ Res 116 : 237-244, 2015.
PubMed
7) Qian L, et al : In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485 : 593-598, 2012.
PubMed
8) Wada R, et al : Induction of human cardiomyocyte-like cells from fibroblasts by defined factors. Proc Natl Acad Sci USA 110 : 12667-12672, 2013.
PubMed
9) Nam YJ, et al : Reprogramming of human fibroblasts toward a cardiac fate. Proc Natl Acad Sci USA 110 : 12667-12672, 2013.
 
10) Fu JD, et al : Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Reports 1 : 235-247, 2013.
 
11) Muraoka N, et al : MiR-133 promotes cardiac reprogramming by directly repressing Snai 1 and silencing fibroblast signatures. EMBO J 33 : 1565-1581, 2014.
 
12) Yamakawa H, et al : Fibroblast Growth Factors and Vascular Endothelial Growth Factor Promote Cardiac Reprogramming under Defined Conditions. Stem Cell Reports 5 : 1128-1142, 2015.
PubMed

XI 急性冠症候群の臨床 ( ST上昇型心筋梗塞を除く )

P.194 掲載の参考文献
1) Roffi M, et al : 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37 : 267-315, 2016.
 
2) Thygesen K et al : Third universal definition of myocardial infarction. Eur Heart J 33 : 2551-2567, 2012.
PubMed
3) Arnsterdam EA, et al : 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline. http://circ.ahajournals.org/content/130/25/e344
 
4) Levine GN, et al : 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction : An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of STLEIevation Myocardial Infarction : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 133 : 1135-1147, 2016.
 
5) 木村一雄, ほか : ST上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
6) 木村剛, ほか : 非ST上昇型急性冠症候群の診療に関するガイドライン (2012年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf
 
7) Habib G, et al : Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009) : the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 30 : 2369-2413, 2009.
 
8) 高山守正 : 東京都CCUネットワーク活動状況報告 2012. http://www.ccunet-tokyo.jp/katsudou_houkoku.html
 
9) 小島淳, 小川久雄 : 熊本急性冠症候群研究会. 冠疾患誌21 : 141-146, 2015.
 
10) 福島県立医科大学医学部循環器・血液内科学講座 : 福島県急性心筋梗塞発症登録調査. https://www.fmu.ac.jp/home/int-medl/Fukushima-AMI/AMI.htm
 
11) 小川久男, 斎藤能彦 : 循環器疾患診療実態調査報告書 (2015年度実施・公表). http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2014web.pdf
 
P.199 掲載の参考文献
1) Fuster V, et al : The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 : 242-250, 1992.
PubMed
2) 日本循環器学会学術委員会ガイドライン : 非ST上昇型急性冠症候群の診療に関するガイドライン (2012年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2012_kimura_h.pdf
 
3) 日本循環器学会学術委員会ガイドライン : AT上昇型急性心筋梗塞の診療に関するガイドライン (2013年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2013_kimura_h.pdf
 
4) Fulton M, et al : Natural history of unstable angina. Lancet 1 : 860-865, 1972.
PubMed
5) Braunwald E : Unstable angina. A classification. Circulation 80 : 410-414, 1989.
PubMed
6) Rentrop KP, et al : Acute myocardial infarction : intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 2 : 354-363, 1979.
PubMed
7) DeWbod MA et al : Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303 : 897-902, 1980.
 
8) Libby P : Molecular bases of the acute coronary syndromes. Circulation 91 : 2844-2850, 1995.
PubMed
9) Schaar JA et al : Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 25 : 1077-1082, 2004.
PubMed
10) Alpert JS, et al : Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 : 959-969, 2000.
 
11) Thygesen K et al : Third universal definition of myocardial infarction. Circulation 126 : 2020-2035, 2012.
PubMed
P.205 掲載の参考文献
1) Rentrop KP, et al : Acute myocardial infarction : intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 2 : 354-363, 1979.
PubMed
2) DeWood MA, et al : Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303 : 897-902, 1980.
PubMed
3) Nobuyoshi M, et al : Progression of coronary atherosclerosis : is coronary spasm related to progression? J Am Coll Cardiol 18 : 904-910, 1991.
PubMed
4) Falk E, et al : Update on acute coronary syndromes : the pathologists' view. Eur Heart J 34 : 719-728, 2013.
PubMed
5) Narula J, et al : Picking Plaques that pop...J Am Coll Cardiol 45 : 1970-1973, 2005.
 
6) Evangelista V, et al : Platelet/polymorphonuclear leukocyte interaction : P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion : role of PSGL-1 as a signaling molecule. Blood 93 : 876-885, 1999.
PubMed
7) Inoue T, et al : Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 107 : 1757-1763, 2003.
PubMed
8) Mazzone A, et al : Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 88 : 358-363, 1993.
PubMed
9) Ikeda H, et al : Increased soluble form of P-selectin in patients with unstable angina. Circulation 92 : 1693-1696, 1995.
PubMed
10) Shimada K, et al : Early intervention with atorvastatin modulates Th1/Th2 imbalance in patients with acute coronary syndrome : from bedsides to bench. Circulation 109 : e213-e214, 2004.
PubMed
11) Aukrust P, et al : Enhanced levels of soluble and membrane-bound CD40 ligand in patients With unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 : 614-620, 1999.
PubMed
12) Biasucci LM, et al : Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol 27 : 611-616, 1996.
 
13) Naruko T, et al : Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106 : 2894-2900, 2002.
PubMed
14) Sanchez de Miguel L, et al : Nitric oxide production by neutrophils obtained from patients during acute coronary syndromes : expression of the nitric oxide synthase isoforms. J Am Coll Cardiol 39 : 818-825, 2002.
PubMed
15) Mehta J, et al : Neutrophil function in ischemic heart disease. Circulation 79 : 549-556, 1989.
PubMed
16) Inoue T, et al : Circulating matrix met alloproteinase-1 and-3 in patients with an acute coronary syndrome. Am J Cardiol 92 : 1461-1464, 2003.
 
17) Fukuda D, et al : Comparison of levels of serum matrix met alloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 97 : 175-180, 2006.
 
P.211 掲載の参考文献
1) Murray CJ, et al : Alternative projections of mortality and disability by cause 1990-2020 : Global Burden of Disease Study. Lancet 349 : 1498-1504, 1997.
PubMed
2) Canto JG, et al : Atypical presentations among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol 90 : 248-253, 2002.
PubMed
3) Culic V, et al : Symptom presentation of acute myocardial infarction : influence of sex, age, and risk factors. Am Heart J 144 : 1012-1017, 2002.
PubMed
4) Brieger D, et al : Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group : insights from the Global Registry of Acute Coronary Events. Chest 126 : 461-469, 2004.
PubMed
5) Keller T, et al : Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361 : 868-877, 2009.
PubMed
6) Giannitsis E, et al : High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem 56 : 642-650, 2010.
PubMed
7) Amsterdam EA et al : 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes : executive summary : areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130 : 2354-2394, 2014.
 
8) Roffi M, et al : 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37 : 267-315, 2016.
 
9) Reichlin T, et al : One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med 172 : 1211-1218, 2012.
PubMed
10) Wang X, et al : Is there an association between time of admission and in-hospital mortality in patients with non-ST-elevation myocardial infarction? A meta-analysis. Sci Rep 5 : 14409, 2015.
PubMed
P.216 掲載の参考文献
1) Amsterdam EA, et al : 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 : e139-228, 2014.
 
2) Stub D, et al : Air Versus Oxygen in ST-Segrnent-Elevation Myocardial Infarction. Circulation 131 : 2143-2150, 2015.
 
3) Antithrombotic Trialists' Collaboration : Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 34 : 71-86, 2002.
 
4) CURRENT-OASIS 7 Investigators, et al : Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363 : 930-942, 2010.
PubMed
5) Weisman SM, et al : Evaluation of tlie benefits and risks of lowdose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 162 : 2197-2202, 2002.
 
6) Nikolsky E, et al : Gastrointestinal bleeding in patients with acute coronary syndromes : incidence, predictors, and clinical implications : analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Uial. J Am Coll Cardiol 54 : 1293-1302, 2009.
 
7) Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators, Yusuf S, Zhao E et al : Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 : 494-502, 2001.
 
8) Wiviott SD, et al : Prasugrel versus clopidogrel in patients With acute coronary syndromes. N Engl J Med 357 : 2001-2015, 2007.
PubMed
9) Saito S, et al : Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome : the PRASFIT, ACS study. Circ J 78 : 1684-1692, 2014.
PubMed
10) Japanese beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators : Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 93 : 969-973, 2004.
PubMed
11) Domanski MJ, et al : Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized chnical trials. J Am Coll Cardiol 33 : 598-604, 1999.
 
12) Rodrigues EJ, et al : Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 115 : 473-479, 2003.
PubMed
13) Cannon CB et al : Comparison of intensive and moderate lipidlowering with statins after acute coronary syndrome. N Engl J Med 350 : 1711-1718. 2001.
 
14) Sakamoto T, et al : Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97 : 1165-1171, 2006.
PubMed
15) Okazaki S, et al : Early statin treatment in patients with acute coronary syndrome : demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event : the ESTABLISH Study. Circulation 110 : 1061-1068, 2004.
PubMed
P.220 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告) 非ST上昇型急性冠症候群の診療に関するガイドライン (2012年改訂版) http://www.j-circ. or. jp/guideline/pdf/JCS2012_kimura_h.pdf
 
2) Sabatine MS, et al : Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction : a comparison of the Thrombolysis In Myocardial Infarction (TIME) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy With Invasive or Conservative Strategy (TACTICS) -TIMI 18 trial. Circulation 109 : 874-880, 2004.
PubMed
3) Fox KA, et al : Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome : prospective multinational observational study (GRACE). BMJ 333 : 1091, 2006.
PubMed
4) Boersma E, et al : Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 101 : 2557-2567, 2000.
 
5) Yan AT, et al : Risk scores for risk stratification in acute coronary syndromes : useful but simpler is not necessarily better. Eur Heart J 28 : 1072-1078, 2007.
 
6) Corcoran D, et al : Risk stratification in non-ST elevation acute coronary syndromes : Risk scores, biomarkers and clinical judgment. Int J Cardiol Heart Vasc 8 : 131-137, 2015.
PubMed
7) Invasive compared with non-invasive treatment in unstable coronary-artery disease : FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 354 : 708-715, 1999.
PubMed
8) Cannon CP, et al : Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 : 1879-1887, 2001.
PubMed
9) Tegn N, et al : Invasive versus conservative strategy in patients aged 80 years or older with non-STelevation myocardial infarction or unstable angina pectoris (After Eighty study) : an open-label randomised controlled trial. Lancet 387 : 1057-1065, 2016.
 
10) Milojevic M, et al : Causes of Death Following PCI Versus CABG in Complex CAD : 5-Year Follow-Up of SYNTAX. J Am Coll Cardiol 67 : 42-55, 2016.
PubMed
11) Angeli E et al : Statins in acute coronary syndrome : very early initiation and benefits. Ther Adv Cardiovasc Dis 6 : 163-174, 2012.
 
12) Ishihara M, et al : Clinical Presentation, Management and Outcome of Japanese Patients With Acute Myocardial Infarction in the Troponin Era-Japanese Registry of Acute Myocardial Infarction Diagnosed by Universal Definition (J-MINUET)-. Circ J 79 : 1255-1262, 2015.
PubMed
P.226 掲載の参考文献
1) Isner JM, et al : Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348 : 370-374, 1996.
PubMed
2) Asahara T et al : Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 : 964-967, 1997.
PubMed
3) Asahara T, et al : Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85 : 221-228, 1999.
PubMed
4) Strauer BE, et al : Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106 : 1913-1918, 2002.
PubMed
5) Schachinger V, et al : Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 355 : 1210-1221, 2006.
PubMed
6) Traverse JH, et al : Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction : the TIME randomized trial. JAMA 308 : 2380-2389, 2012.
PubMed
7) Traverse JH, et al : Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function : the LateTIME randomized trial. JAMA 306 : 2110-2119, 2011.
PubMed
8) Perin EC, et al : Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure : the FOCUSCCTRN trial. JAMA 307 : 1717-1726, 2012.
PubMed
9) Stirder D, et al : Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction : effects on global left ventricular function. Circulation 127 : 1968-1979, 2013.
PubMed
10) Pittenger ME et al : Multilineage potential of adult human mesenchymal stem cells. Science 284 : 143-147, 1999.
 
11) Zuk PA et al : Multilineage cells from human adipose tissue : implications for cell-based therapies. Tissue Eng 7 : 211-228, 2001.
PubMed
12) Zuk PA, et al : Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13 : 4279-4295, 2002.
PubMed
13) Murohara T, et al : Autologous adipose-derived regenerative cells for therapeutic angiogenesis. Curr Pharm Des 15 : 2784-2790, 2009.
PubMed
14) Kondo K, et al : Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 29 : 61-66, 2009.
PubMed
15) Traktuev DO, et al : A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res 102 : 77-85, 2008.
 
16) Nagasawa T et al : Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeHciency virus 1 entry coreceptor fusin. Proc Natl Acad Sci USA 93 : 14726-14729, 1996.
PubMed
17) Hiasa K, et al : Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway : next-generation chemokine therapy for therapeutic neovascularization. Circulation 109 : 2454-2461, 2004.
PubMed
18) Ishii M, et al : Enhanced angiogenesis by transplantation of mesenchymal stem cell sheet created by anovel magnetic tissue engineering method. Arterioscler Thromb Vasc Biol 31 : 2210-2215, 2011.
 
19) Cai L, et al : IFATS collection : Human adipose tissue-derived stem cells induce angiogenesis and nerve sprouting following myocardial infarction, in conjunction with potent preservation of cardiac function. Stem Cells 27 : 230-237, 2009.
PubMed
20) Schenke-Layland K, et all Adipose tissue-derived cells improve cardiac function following nlyocardial infarction. J Surg Res 153 : 217-223, 2009.
 
21) Pittenger MF, et al : Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95 : 9-20, 2004.
PubMed
22) Zhang M, et al : Cardiomyocyte grafting for cardiac repair : graft cell death and anti-death strategies. J Mol Cell Cardiol 33 : 907-921, 2001.
PubMed
23) Ishii M, et al : Multilayered adipose-derived regeneradve cell sheets created by a novel magnetite tissue engineering method for myocardial infarction. Int J Cardiol 175 : 545-553, 2014.
PubMed
24) Houtgraaf JH, et al : First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 59 : 539-540, 2012.
PubMed
25) Perin EC, et al : Adipose-derived regenerative cells in patients with ischemic cardiomyopathy : The PRECISE Trial. Am Heart J 168 : 88-95 e2, 2014.
 
26) Suncion VY, et al : Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally? : An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ Res 114 : 1292-1301, 2014.
PubMed
27) Malliaras K, et al : Intracoronary cardiosphere-derived cells after myocardial infarction : evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Deroved aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 63 : 110-122, 2014.
PubMed
28) Bartunek J, et al : Cardiopoietic stem cell therapy in heart failure : the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specMed biologics. J Am Coll Cardiol 61 : 2329-2338, 2013.
 
29) Takahashi K, et al : Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 : 663-676, 2006.
PubMed
P.232 掲載の参考文献
1) Guidelines for management of acute coronary syndrome without persistent ST segment elevation (JCS 2012)
 
2) Awad HH, et al : Cardiogenic shock complicating acute coronary syndromes : insights from the Global Registry of Acute Coronary Events. Am Heart J 163 : 963-971, 2012.
PubMed
3) Holmes DR, et al : Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 100 : 2067-2073, 1999.
PubMed
4) Keeley EC, et al : Left ventricular mural thrombus after acute myocardial infarction. Clin Cardiol 19 : 83-86, 1996.
 
5) Amsterdam EA, et al : 2014 AHA/ACC Guideline for the Management of PatientS With Non-ST-Elevation Acute Coronary Syndromes : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130 : 2354-2394, 2014.
 
6) Hjalmarson A : Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 80 : 35J-3gJ, 1997.
PubMed
7) Epstein AE, et al : 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 61 : e6-75, 2013.
 
8) Rioufol G, et al : Multiple atherosclerotic plaque rupture in acute coronary syndrome : a three-vessel intravascular ultrasound study. Circulation 106 : 804-808, 2002.
PubMed
9) Jugdutt BI : Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation 115 : 288-291, 2007.
PubMed
10) Alexander KP, et al : Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J 155 : 1047-1053, 2008.
PubMed
11) Rao SV, et al : Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 : 1193-1204, 2007.
PubMed
12) Wakabayashi K, et al : Provoked coronary spasm predicts adverse outcome in patients with acute myocardial infarction : a novel predictor of prognosis after acute myocardial infarction. J Am Coll Cardiol 52 : 518-522, 2008.
PubMed
13) HELLERSTEIN HK, et al : Incidence of thrombo-embolic lesions accompanying myocardial infarction. Am Heart J 33 : 443-452, 1947.
PubMed

XII 虚血性心筋症の臨床

P.240 掲載の参考文献
1) Dunlay SM, et al : Risk factors for heart failure : a population-based case-control study. Am J Med 122 : 1023-1028, 2009.
PubMed
2) He J, et al : Risk factors for congestive heart failure in US men and women : NHANES I epidemiologic follow-up study. Arch Intern Med 161 : 996-1002, 2001.
PubMed
3) Bursi E et al : Heart failure and death after myocardial infarction in the community : the emerging role of mitral regurgitation. Circulation 111 : 295-301, 2005.
 
4) Felker GM, et al : A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 39 : 210-218, 2002.
PubMed
5) Velazquez EJ, et al : Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Eng J Med 364 : 1607-1616, 2011.
 
6) Deja MA, et al : Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation 125 : 2639-2648, 2012.
PubMed
7) Fattouch K, et al : POINT : Efncacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafijng in patients with moderate ischemic mitral valve regurgitation : a randomized trial. J Thorac Cardiovasc Surg 138 : 278-285, 2009.
 
8) Chan KM, et al : Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation : final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation 126 : 2502-2510, 2012.
 
9) Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), et al : Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33 : 2451-2496, 2012.
 
10) Nishimura RA et al : 2014 AHA/ACC Guidehne for the Management of Padents With Valvular Heart Disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 : e521-643, 2014.
 
11) Smith PK et al : Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 371 : 2178-2188, 2014.
PubMed
P.245 掲載の参考文献
1) Kubo M, et al : Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community : the Hisayama study. Stroke 34 : 2349-2354, 2003.
 
2) Kiyohara Y, et al : Smoking and cardiovascular disease in the general population in Japan. J Hypertens 8 (Suppl 5) : S9-15, 1990.
 
3) Kitamura A et al : Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003 : the Akita-Osaka study. J Am Coll Cardiol 52 : 71-79, 2008.
PubMed
4) Rumana N, et al : Trend of increase in the incidence of acute myocardial infarction in a Japanese population : Takashima AMI Registry, 1990-2001. Am J Epidemiol 167 : 1358-1364, 2008.
 
5) WHO : World Health Statistics Annual 1997-2003.
 
6) Hozawa A, et al : Is weak association between cigarette smoking and cardiovascular disease mortality observed in Japan explained by low total cholesterol? NIPPON DATA80. Int J Epidemiol 36 : 1060-1067, 2007.
PubMed
7) Kosuge M, et al : Sex differences in early mortality of patients undergoing primary stenting for acute myocardial infarction. Circ J 70 : 217-221, 2006.
PubMed
8) Kawano H, et al : Sex differences of risk factors for acute myocardial infarction in Japanese patients. Circ J 70 : 513-517, 2006.
PubMed
9) NIPPON DATA80 Research Group : Risk assessment chart for death from cardiovascular disease based on a 19-year follow」up study of a Japanese representative populadon. Circ J 70 : 1249-1255, 2006.
 
10) Ohkawa S, et al : Stenotic lesions and length of the left main coronary artery in the aged, Jpn Heart J 30 : 779-788, 1989.
PubMed
11) Wen CP, et al : Minimum amount of physical activity for reduced mortality and eXtended life expectancy : a prospective cohort study. Lancet 378 : 1244-1253, 2011.
PubMed
12) Haykowsky M, et al : A meta-analysis of the effects of exercise training on left ventricular remodeling following myocardial infarction : start early and go longer for greatest exercise benefits on remodeling. Trials 12 : 92, 2011.
 
P.250 掲載の参考文献
1) Burch GE, et al : Ischemic cardiomyopathy. Am Heart J 79 : 291-292, 1970.
PubMed
2) Sun Y, et al : Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol 28 : 851-858, 1996.
 
3) Mill JG, et al : Time course of changes in heart rate and sympathetic tone after coronary artery ligation in rats. Braz J Med Biol Res 24 : 855-858, 1991.
PubMed
4) Benedict CR, et al : Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 94 : 690-697, 1996.
PubMed
5) Kinugawa S, et al : Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice : role of oxidative stress. Circ Res 87 : 392-398, 2000.
PubMed
6) Ide T, et al : Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 88 : 529-535, 2001.
PubMed
7) Guyton KZ, et al : Activation of mitogen-activated protein kinase by H202. Role in cell survival following oxidant injury. J Biol Chem 271 : 4138-4142, 1996.
 
8) Kwon SH, et al : H2O2 regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol 35 : 615-621, 2003.
PubMed
9) Cesselli D, et al : Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res 89 : 279-286, 2001.
 
10) Hayashidani S, et al : Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 108 : 2134-2140, 2003.
PubMed
11) Sobirin MA, et al : Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. Circ Res 111 : 1037-1047, 2012.
PubMed
12) Antoons G, et al : Targeting calcium handling in arrhythmias. Europace 10 : 1364-1369, 2008.
PubMed
13) Boyden PA, et al : Nonuniform Ca2+ transients in arrhythmogenic Purkinje cells that survive in the infarcted canine heart. Cardiovasc Res 57 : 681-693, 2003.
PubMed
14) Miura M, et al : The pathophysiology of myocardial stunning : reversibility, accumulation and continuity of the ischemic myocardial damage after reperfusion. Jpn Circ J 55 : 868-877, 1991.
PubMed
15) Fallavollita JA, et al : Regional alterations in SR Ca2+ -ATPase, phospholamban, and HSP-70 expression in chronic hibernating myocardium. Am J Physiol 277 : H1418-1428, 1999.
 
P.254 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2009-2010年度合同研究班報告) 拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2011_tomoike_h.pdf
 
2) Buja ML, et al : Cardiovascular pathology, fourth edition, p239-270, Academic Press, 2015.
 
3) Basso C, et al : The metamorphosis of myocardial infarction following coronary recanalization. Cardiovasc Pathol 19 : 22-28, 2010.
 
P.259 掲載の参考文献
1) Levine RA, et al : Ischemic mitral regurgitation on the threshold of a solution : from paradoxes to unifying concepts. Circulation 112 : 745-758, 2005.
PubMed
2) Grigioni E et al : Ischemic mitral regurgitation : long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 103 : 1759-1764, 2001.
 
3) Lancellotti R et al : Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 42 : 1921-1928, 2003.
 
4) Yamano T, et al : Exercise-induced changes of functional mitral regtirgitation in asymptomatic or mildly symptomatic patients with idiopathic dilated cardiomyopathy. Am J Cardiol 102 : 481-485, 2008.
PubMed
5) Vahanian A, et al : Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33 : 2451-2496, 2012.
PubMed
6) Nishimura RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 : e57-185, 2014.
 
7) Levine RIY Dynamic mitral regurgitation-more than meets the eye. N Engl J Med 351 : 1681-1684, 2004.
 
8) Pierard LA, et al : The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. N Engl J Med 351 : 1627-1634, 2004.
PubMed
9) Lancellotti B et al : How to manage ischaemic mitral regurgitation, Heart 94 : 1497-1502, 2008.
 
10) Cerisano G, et al : Prognostic implications of restrictive left ventricular filling in reperfused anterior acute myocardial infarction. J Am Coll Cardiol 37 : 793-799, 2001.
PubMed
11) Moller JE, et al : Independent prognostic importance of a restrictive left ventricular filling pattern after myocardial infarction : an individual patient meta-analysis : Meta-Analysis Research Group in Echocardiography acute myocardial infarction. Circulation 117 : 2591-2598, 2008.
 
12) Hillis GS, et al : Noninvasive estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol 43 : 360-367, 2004.
 
13) Moller JE, et al : Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am Heart J 151 : 419-425, 2006.
PubMed
14) Antoni ML, et al : Prognostic importance of strain and strain rate after acute myocardial infarction. Eur Heart J 31 : 1640-1647, 2010.
PubMed
15) Moller JE, et al : Left atrial volume : a powerful predictor of survival after acute myocardial infarction. Circulation 107 : 2207-2212, 2003.
PubMed
P.263 掲載の参考文献
1) Burch GE, et al : Ischemic cardiomyopathy. Am Heart J 79 : 291-292, 1970.
PubMed
2) Gaemperli O, et al : Validation of a new cardiac image fusion software for three-dimensional integration of myocardial perfusion SPECT and stand-alone 64-slice CT angiography. Eur J Nucl Med Mol Imaging 34 : 1097-1106, 2007.
PubMed
3) Koyama Y, et al : Assessment of reperfused acute myocardial infarction with two-phase contrastenhanced helical CT : prediction of left ventricular function and wall thickness. Radiology 235 : 804-811, 2005.
PubMed
4) Ota S, et al : Impact of low signal intensity assessed by cine magnetic resonance imaging on detection of poorly viable myocardium in patients with prior myocardial infarction. Int Heart J 56 : 273-277, 2015.
PubMed
5) Kim Rl, et al : Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100 : 1992-2002, 1999.
 
6) Wu E, et al : Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357 : 21-28, 2001.
PubMed
7) Wagner A et al : Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 47 : 2027-2033, 2006.
PubMed
8) Wagner A et al : Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts : an imaging study. Lancet 361 : 374-379, 2003.
PubMed
9) Beek AM, et al : Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol 42 : 895-901, 2003.
PubMed
10) Kim RJ, et al : The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 : 1445-1453, 2000.
PubMed
P.268 掲載の参考文献
1) Braunwald E : Biomarkers in heart failure. N Engl J Med 358 : 2148-2159, 2008.
PubMed
2) Tanaka K, et al : Cardiac emergency triage and therapeutic decisions using whole blood rapid troponin Ttest for patients with suspicious acute coronary syndrome. Jpn Circ J 65 : 424-428, 2001.
 
3) Haltern G, et al : Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction, Am J Cardiol 105 : 1-9, 2010.
PubMed
4) Reichlin T, et al : Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361 : 858-867, 2009.
PubMed
5) Nishio Y, et al : Cardiac troponin T vs other biochemical markers in patients with congestive heart failure. Circ J 71 : 631-635, 2007.
PubMed
6) de Lemos JA et al : Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304 : 2503-2512, 2010.
PubMed
7) Sabatine MS, et al : Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes : simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 : 1760-1763, 2002.
 
8) Keller T, et al : Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361 : 868-877, 2009.
PubMed
9) Mukoyama M, et al : Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 : 1402-1412, 1991.
PubMed
10) Yasue H, et al : Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 : 195-203, 1994.
PubMed
11) Yoshimura M, et al : Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in padents with congestive heart failure. Circulation 87 : 464-469, 1993.
 
12) Jones CB, et al : Matrix met alloproteinases : areview of their structure and role in acute coronary syndrome. Cardiovasc Res 59 : 812-823, 2003.
 
13) Vasan RS, et al : Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction : the Framingham Heart Study. Circulation 107 : 1486-1491, 2003.
PubMed
P.275 掲載の参考文献
1) Imamura T, et al : Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 78 : 2240-2249, 2014.
PubMed
2) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 : 1429-1435, 1987.
 
3) Correction : Effects of an Angiotensin-Converting-Enzyme Inhibitor, kmipril, 0n Cardiovascular Events in High-Risk Patients. N Engl J Med 342 : 1376, 2000.
 
4) 慢性心不全治療ガイドライン (2010年改訂版), 2010. http://www.j-circ.or. jp/guideline/pdf/JCS2010_matsuzaki_h.pdf
 
5) Packer M, et al : The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US. Carvedilol Heart Failure Study Group. N Engl J Med 334 : 1349-1355, 1996.
 
6) The Cardiac lnsufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet 353 : 9-13, 1999.
 
7) Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 : 2001-2007, 1999.
PubMed
8) Dargie HJ : Effect of carvedilol on outcome after myocardial infarction in patients With left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet 357 : 1385-1390, 2001.
PubMed
9) Packer M, et al : Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
PubMed
10) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
11) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
12) Zannad F, et al : Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 : 11-21, 2011.
PubMed
13) Fox K et al : Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL) : a randomised, double-blind, placebo-controlled trial. Lancet 372 : 807-816, 2008.
PubMed
14) Swedberg K, et al : Ivabradine and outcomes in chronic heart failure (SHIFT) : arandomised placebocontrolled study. Lancet 376 : 875-885, 2010.
PubMed
15) McMurray JJ, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 : 993-1004, 2014.
PubMed
P.281 掲載の参考文献
1) Shah PJ, et al : Survival after myocardial revascularization for ischemic cardiomyopathy : a prospective ten-year follow-up study. J Thorac Cardiovasc Surg 126 : 1320-1327, 2003.
PubMed
2) Cho Y, et al : Non-heart transplant surgical approaches with left ventricular restoration and mitral valve operation for advanced ischaemic cardiomyopathy. Eur J Cardiothorac Surg 46 : 849-856, 2014.
PubMed
3) Jones RH, et al : Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 360 : 1705-1717, 2009.
 
4) Cho Y, et al : Long-term results and mid-term features of left ventricular reconstruction procedures on left ventricular volume, geometry, function and mitral regurgitation. Eur J Cardiothorac Surg 42 : 462-469, 2012.
PubMed
5) Menicanti L, et al : The Dor procedure : what has changed after fifteen years of clinical practice? J Thorac Cardiovasc Surg 124 : 886-890, 2002.
PubMed
6) Dor V, et al : Favorable effects of left ventricular reconstruction in patients excluded from the Surgical Treatments for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg 141 : 905-916, 916. e1-4, 2011.
 
7) Buckberg G : Outcomes of left ventricular reconstruction when established parameters are followed, and subsequent questions. Eur J Cardiothorac Surg 42 : 393-397, 2012.
PubMed
8) Di Donato M, et al : End-systolic volume following surgical ventricular reconstruction impacts survival in patients with ischaemic dilated cardiomyopathy. Eur J Heart Fail 12 : 375-381, 2010.
PubMed
9) Isomura T et al : Indication of posterior restoration and surgical results in patients with dilated cardiomyopathy. Eur J Cardiothorac Surg 38 : 171-175, 2010.
PubMed
10) Isomura T et al : Volume reduction rate by surgical ventricular restoration determines late outcome in ischaemic cardiomyopathy. Eur J Heart Fail 13 : 423-431, 2011.
PubMed
11) Mickleborough LL, et al : Left ventricular reconstruction : Early and late results. J Thorac Cardiovasc Surg 128 : 27-37, 2004.
PubMed
12) Matsui Y, et al : Integrated overlapping ventriculoplasty combined with papillary muscle plication for severely dilated heart failure. J Thorac Cardiovasc Surg 127 : 1221-1223, 2004.
PubMed
13) Yaku H, et al : Endocardial linear exclusion technique for lateral wall : anew technique for ventricular restoration. Interact Cardiovasc Thorac Surg 7 (suppl 3) : S254, 2008.
 
14) Wakasa S, et al : Risk scores for predicting mortality after surgical ventricular reconstruction for ischemic cardiomyopathy : results of a Japanese multicenter study. J Thorac Cardiovasc Surg 147 : 1868-1874, 1874. e1-2, 2014.
 
15) Magne J, et al : Ischemic mitral regurgitation : acomplex multifaceted disease. Cardiology 112 : 244-259, 2009.
 
P.286 掲載の参考文献
1) Wakasa S, et al : Risk scores for predicting mortality after surgical ventricular reconstruction for ischemic cardiomyopathy : results of a Japanese multicenter study. J Thorac Cardiovasc Surg 147 : 1868-1874, 1874e1861-1862, 2014.
 
2) Lund LH, et al : The Registry of the International Society for Heart and Lung Transplantation : Thirtysecond Official Adult Heart Transplantation Report-2015 ; Focus Theme : Early Graft Failure. J Heart Lung Transplant 34 : 1244-1254, 2015.
PubMed
3) Nakatani T, et al : The Registry Report of Heart Transplantation in Japan (1999-2014). Circ J 80 : 44-50, 2016.
PubMed
4) Martinelli L, et al : Different results of cardiac transplantation in patients with ischemic and dilated cardiomyopathy. Eur J Cardiothorac Surg 9 : 644-650, 1995.
PubMed
5) Aziz T, et al : Pulmonary vein gas analysis for assessing of donor lung function. J Heart Lung Transplant 20 : 255, 2001.
PubMed
6) Gungor H, et al : Comparison of heart transplantation patients with ischemic and idiopathic dilated cardiomyopathy. Transplant Proc 43 : 3847-3850, 2011.
PubMed
7) Guddeti RR, et al : Ischemic cardiomyopathy is associated with coronary plaque progression and higher event rate in patients after cardiac transplantation. J Am Heart Assoc 3 : 2014.
PubMed
8) Raichlin E, et al : Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. Transplantation 85 : 963-968, 2008.
PubMed
9) Rosing K, et al : Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Atherosclerosis 230 : 164-170, 2013.
PubMed
10) Kirklin JK et al : Seventh INTERMACS annual report : 15,000 patients and counting. J Heart Lung Transplant 34 : 1495-1504, 2015.
PubMed
11) Tsiouris A, et al : Ischemic versus nonischemic dilated cardiomyopathy : the implications of heart failure etiology on left ventricular assist device outcomes. ASAIO J 59 : 130-135, 2013.
PubMed
12) Atluri P, et al : Ventricular assist device implant in the elderly is associated with increased, but respectable risk : a multi-institutional study. Ann Thorac Surg 96 : 141-147, 2013.
 
13) Cowger J, et al : Predicting survival in patients receiving continuous flow left ventricular assist devices : the HeartMate II risk score. J Am Coll Cardiol 61 : 313-321, 2013.
PubMed
14) Sorabella RA, et al : Comparison of outcomes after heart replacement therapy in patients over 65 years old. Ann Thorac Surg 99 : 582-588, 2015.
PubMed
15) Shiba N, et al : Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-first report from the CHART-2 study. Circ J 75 : 823-833, 2011.
PubMed
P.291 掲載の参考文献
1) Laflamme MA, et al : Heart regeneration. Nature 473 : 326-335, 2011.
PubMed
2) Evans MJ, et al : Establishment in culture of pluripotential cells from mouse embryos. Nature 292 : 154-156, 1981.
PubMed
3) Thomson JA, et al : Embryonic stem cell lines derived from human blastocysts. Science 282 : 1145-1147, 1998.
PubMed
4) Takahashi K, et al : Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by denned factors. Cell 126 : 663-676, 2006.
 
5) Takahashi K et al : Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 : 861-872, 2007.
PubMed
6) Tohyama S, et al : Distinct metabolic flow enables large-scale purincation of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12 : 127-137, 2013.
PubMed
7) Shiba Y, et al : Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489 : 322-325, 2012.
PubMed
8) Seldne H, et al : Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection. Tissue Eng. Part A 17 : 2973-2980, 2011.
 
9) Menasch6 P, et al : Human embryonic stem cel1-derived cardiac progenitors for severe heart failure treatment : first clinical case report. Eur Heart J 36 : 2011-2017, 2015.
 
10) Roell W, et al : Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 450 : 819-824, 2007.
PubMed
11) Chong JJ, et al : Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510 : 273-277, 2014.
PubMed
P.296 掲載の参考文献
1) Tei C : Waon therapy : soothing warmth therapy. J Cardiol 49 : 301-304, 2007.
PubMed
2) Miyata M, et al : Waon therapy for cardiovascular disease : innovative therapy for the 21st century. Circ J 74 : 617-621, 2010.
PubMed
3) Tei C, et al : Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. Circulation 91 : 2582-2590, 1995.
PubMed
4) Kihara T, et al : Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure. J Am Coll Cardiol 39 : 754-759, 2002.
PubMed
5) Miyata M, et al : Beneficial effects of Waon therapy on patients With chronic heart failure : results of a prospective multicenter study. J Cardiol 52 : 79-85, 2008.
 
6) Kihara T, et al : Effects of repeated sauna treatment on ventricular arrhythmias in patients with chronic heart failure. Circ J 68 : 1146-1151, 2004.
PubMed
7) Khara T, et al : Waon therapy improves the prognosis of patients with chronic heart failure. J Cardiol 53 : 214-218, 2009.
 
8) Kuwahata S, et al : Improvement of autonomic nervous activity by Waon therapy in patients with chronic heart failure. J Cardiol 57 : 100-106, 2011.
PubMed
9) Ikeda Y, et al : Effect of repeated sauna therapy on survival in TO-2 cardiomyopathic hamsters with heart failure. Am J Cardiol 90 : 343-345, 2002.
 
10) Ikeda Y, et al : Repeated sauna therapy increases arterial endothelial nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. Circ J 69 : 722-729, 2005.
PubMed
11) Fujita S, et al : Effect of Waon therapy on oxidative stress in chronic heart failure. Circ J 75 : 348-356, 2011.
 
12) Akasaki Y, et al : Repeated thermal therapy up-regulates endothelial nitric oxide synthase and augments angiogenesis in a mouse model of hindlimb ischemia. Circ J 70 : 463-470, 2006.
 
13) Tei C, et al : Waon therapy improves peripheral arterial disease. J Am Coll Cardiol 50 : 2169-2171, 2007.
PubMed
14) Tei C, et al : Successful thermal therapy for end-stage peripheral artery disease. J Cardiol 47 : 163-164, 2006.
PubMed
15) Sobajima M, et al : Repeated sauna therapy improves myocardial perfusion in patients with chronically occluded coronary artery-related ischemia. Int J Cardiol 167 : 237-243, 2013.
PubMed

XIII 虚血性心疾患における不整脈の臨床

P.305 掲載の参考文献
1) Harris AS, Rojas AG : The initiation of ventricular fibrillation due to coronary occlusion. Exp Med Surg 1 : 105-122, 1948.
 
2) Noma A : ATP-regulated K+ channels in cardiac muscle. Nature 305 : 147-148, 1983.
PubMed
3) Antzelevitch C, et al : J-wave syndromes : Brugada and early repolarization syndromes. Heart Rhythm 12 : 1852-1866, 2015.
PubMed
4) El-Sherif N, et al : Re-entrant ventricular arrhythmias in the late myocardial infarction period. 1. Conduction characteristics in the infarction zone. Circulation 55 : 686-702, 1977.
PubMed
5) De Bakker JMT, et al : Pathophysiological correlates of ventricular tachycardia in hearts with a healed infarct. In cardiac Electrophysiology : From cell to Bedside. 3rd Ed. (ed by Zipes P, et al.). p413-422. WB Saunders, Philadelphia. 1999.
 
6) Gussak I, et al : Electrocardiographic "lambda" wave and primary idiopathic cardiac asystole : a new clinical syndrome? J Electrocardiol 37 : 105-107, 2004.
PubMed
7) Jastrzebski M, et al : Jwave : novel risk marker for ventricular fibrillation? Heart Rhythm 6 : 829-835, 2009.
 
8) Aizawa Y, et al : Characteristics of electrocardiographic repolarization in acute myocardial infarction complicated by ventricular fibrillation. J EIectrocardiol 45 : 252-259, 2012.
PubMed
9) Ogtiro T, et al : Electrical alternans induced by a brief period of myocardial ischemia during percutaneous coronary intervention : The characteristic ECG morphology and relationship to mechanical alternans. Heart Rhythm 12 : 2272-2277, 2015.
PubMed
10) Nakayama M, et al : J-waves in patients With an acute ST-elevation myocardial infarction who underwent successfUI percutaneous coronary intervention : prevalence, pathogenesis, and clinical implication. Europace 15 : 109-115, 2013.
 
11) Szumowski L, et al : Mapping and ablation of polymorphic ventricular tachycardia after myocardial infarction. J Am Coll Cardiol 44 : 1700-1706, 2004.
PubMed
12) Bansch D, et al : Successful catheter ablation of electrical storm after myocardial infarction. Circulation 108 : 3011-3016, 2003.
PubMed
13) Soejima K, et al : Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction : short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. Circulation 104 : 664-669, 2001.
PubMed
14) Jennings RB, et al : Ischemic tissue injury. Am J pathol 81 : 179-198, 1975.
PubMed
P.311 掲載の参考文献
1) Piccini JP, et al : Predictors of sudden cardiac death change with time after myocardial infarction : results from the VALIANT trial. Eur Heart J 31 : 211-221, 2010.
PubMed
2) Sato A, et al : Analysis of J waves during myocardial ischaemia. Europace 14 : 715-723, 2012.
PubMed
3) Yoshihisa N, et al : Early Repolarization Is an Independent Predictor of Occurrences of Ventricular Fibrillation in the Very Early Phase of Acute Myocardial Infarction. Circ Arrhythm Electrophysiol 5 : 506-513, 2012.
 
4) Schmidt G, et al : Heart-rate turbulence after ventricular prematUre beats as a predictor mortality after acute myocardial infarction. Lancet 353 : 1390-1396, 1999.
PubMed
5) Exner DV, et al : Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol 50 : 2275-2284, 2007.
PubMed
6) De Ferrari GM, et al : Baroreflex sensitivity predicts long-term cardiovascular mortality after myocardial infarction even in patients with preserved left ventricular function. J Am Coll Cardiol 50 : 2285-2290, 2007.
PubMed
7) La Rovere MT, et al : Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 351 : 478-484, 1998.
PubMed
8) 田邊晃久 : 心臓突然死を予知するための不整脈ノンインベイシブ検査, 医学書院 : 2-8, 2010.
 
P.315 掲載の参考文献
1) Reiner JS, et al : Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. GUSTO-1 Angiographic Investigators. Circulation 94 : 2441-2446, 1996.
PubMed
2) Al-Khatib SM, et al : Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction : results from the GUSTO-III trial. Am Heart J 145 : 515-521, 2003.
PubMed
3) Solomon SD, et al : Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352 : 2581-2588, 2005.
 
4) Okumura K JCS Joint Working Group : Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JSC 2011). Circ J 77 : 249-274, 2013.
 
5) Stevenson WG, et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation. 88 : 1647-1670, 1993.
PubMed

XIV 無症候性心筋虚血の臨床

P.321 掲載の参考文献
1) Schang SJ, et al : Transient asymptomatic ST segment depression during daily activity. Am J Cardiol 39 : 396-402, 1977.
PubMed
2) Deedwania PC, et al : Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 81 : 748-756, 1990.
PubMed
3) Deanfield JE, et al : Myocardial ischaemia during daily life in patients with stable angina : its relation to symptoms and heart rate changes. Lancet 2 : 753-758, 1983.
PubMed
4) Deedwania PC, et al : Role of myocardial oxygen demand in the pathogenesis of silent ischemia during daily life. Am J Cardiol 70 : 19F-24F, 1992.
PubMed
5) Deedwania PC, et al : Pathophysiology of silent myocardial ischemia during daily life. Circulation, 82, 1296-1304, 1990.
PubMed
6) Gottheb SO, et al : Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 314 : 1214-1219, 1986.
PubMed
7) Gottlieb SO, et al : Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients. JAMA 259 : 1030-1035, 1988.
PubMed
8) Tzivoni D, et al : Prognostic significance of ischemic episodes in patients with previous myocardial infarction. Am J Cardiol 62 : 661-664, 1988.
PubMed
9) Deedwania PC, et al : Prevalence and patterns of silent myocardial ischemia during daily life in stable angina patients receiving conventional antianginal drug therapy. Am J Cardiol 65 : 1090-1096, 1990.
PubMed
10) Deedwania PC, et al : Silent myocardial ischemia. A clinical perspective. Arch Intern Med 151 : 2373-2382, 1991.
PubMed
11) Langou RA, et al : Predictive accuracy of coronary artery calcification and abnormal exercise test for coronary artery disease in asymptomatic men. Circulation 62 : 1196-1203, 1980.
PubMed
12) Yeung AC, et al : Effects of asymptomatic ischemia on long-term prognosis in chronic stable coronary disease. Circulation 83 : 1598-1604, 1991.
PubMed
13) Sharaf BL, et al : Adetailed angiographic analysis of patients with ambulatory electrocardiographic ischemia : results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) study angiographic core laboratory. J Am Coll Cardiol 29 : 78-84, 1997.
 
14) Madsen JK et al : Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMD. DANish trial in Acute Myocardial Infarction. Circulation 96 : 748-755, 1997.
PubMed
15) Erne P, et al : Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction : the SWISSI II randomized controlled trial. JAMA 297 : 1985-1991, 2007.
PubMed
16) Fazzini PE et al : Epidemiology of silent myocardial ischemia in asymptomatic middle-aged men (the ECCIS Project). Am J Cardiol 72 : 1383-1388, 1993
 
17) Zellweger MJ, et al : Threshold, incidence, and predictors of prognostically high-risk silent ischemia in asymptomatic patients without prior diagnosis of coronary artery disease. J Nucl Cardiol 16 : 193-200, 2009.
PubMed
P.326 掲載の参考文献
1) Gill JB, et al : Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med 334 : 65-70, 1996.
PubMed
2) Gottlieb SO, et al : Silent ischemia predicts infarction and death during 2 year follow・up of unstable angina. J Am Coll Cardiol 10 : 756-760, 1987.
 
3) Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Am J Cardiol 79 : 134-139, 1997.
 
4) Weiner DA et al : Risk of developing an acute myocardial infarction or sudden coronary death in patients with exercise-induced silent myocardial ischemia. A report from the Coronary Artery Surgery Study (CASS) registry. Am J Cardiol 62 : 1155-1158, 1988.
PubMed
5) Greenland P, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 56 : e50-103, 2010.
 
6) Zellweger MJ, et al : Threshold, incidence, and predictors of prognostically high-risk silent ischemia in asymptomatic patients without prior diagnosis of coronary artery disease. J Nucl Cardiol 16 : 193-200, 2009.
PubMed
7) Young LH, et al : Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes : the DIAD study : a randomized controlled trial. JAMA 301 : 1547-1555, 2009.
PubMed
8) Zellweger MJ, et al : Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. J Am Coll Cardiol 42 : 33-40, 2003.
PubMed
9) Eisenberg MJ, et al : Evaluation of routine functional testing after percutaneous coronary intervention. Am J Cardiol 93 : 744-747, 2004.
PubMed
10) Deanfield JE, et al : Medical treatment of myocardial ischemia in coronary artery disease : effect of drug regime and irregular dosing in the CAPE II trial. J Am Coll Cardiol 40 : 917-925, 2002.
 
11) Von Arnim T : Prognostic significance of transient ischemic episodes : response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (HBBs) follow-up. J Am Coll Cardiol 28 : 20-24, 1996.
 
12) Davies RF, et al : A symptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up : outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 95 : 2037-2043, 1997.
 
13) Erne R et al : Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction : the SWISSI II randomized controlled trial. JAMA 297 : 1985-1991, 2007.
 
14) Gosselin G, et al : Effectiveness of percutaneous coronary intervention in patients with silent myocardial ischemia (post hoc analysis of the COURAGE trial). Am J Cardiol 109 : 954-959, 2012.
PubMed
P.331 掲載の参考文献
1) Fleg JL, et al : Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation 81 : 428-436, 1990.
PubMed
2) Weiner DA, et al : Significance of silent myocardial ischemia during exercise testing in patients with coronary artery disease. Am J Cardiol 59 : 725-729, 1987.
PubMed
3) 石田大, ほか : 無症候性心筋虚血の長期予後に関する疫学的検討. 日本臨床生理学会誌 33 : 45-54, 2003.
 
4) Schelbert EB, et al : Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA 308 : 890-896, 2012.
PubMed
5) Yamasaki Y, et al : Prognostic value of gated myocardial perfusion imaging for asymptomatic patients with type 2 diabetes : the J-ACCESS 2 investigation. Diabetes Care 33 : 2320-2326, 2010.
 
6) Erne R et al : Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I : the Swiss Interventional study on Silent Ischaemia type I (SWISSI D : a randomized, controlled pilot study. Eur Heart J 28 : 2110-2117, 2007.
 
7) Rogers WJ, et al : Asymptomatic Cardiac Ischemia Pilot (ACIP) study : outcome at l year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators. J Am Coll Cardiol 26 : 594-605, 1995.
PubMed
8) Sedlis SP, et al : Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. N Engl J Med 373 : 1937-1946, 2015.
PubMed
9) Aldweib N, et al : Impact of repeat myocardial revascularization on outcome in patients with silent ischemia after previous revascularization. J Am Coll Cardiol 61 : 1616-1623, 2013.
PubMed

XV 心不全の臨床

P.339 掲載の参考文献
1) 平成23年版 高齢社会白書. p. 13.
 
2) hevy D, et al : Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347 : 1397-1402, 2002.
 
3) Bleumink GS, et al : Quantifying the heart failure epidemic : prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25 : 1614-1619, 2004.
PubMed
4) Fang J, et al : Heart failure-related hospitalization in the U. S., 1979 to 2004. J Am Coll Cardiol 52 : 428-434, 2008.
 
5) Blecker S, et al : Heart failure-associated hospitalizations in the United States. J Am Coll Cardiol 61 : 1259-1267, 2013.
PubMed
6) Gheorghiade M, et al : Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 296 : 2217-2226, 2006.
PubMed
7) Adams KF, et al : Characteristics and outcomes of patients hospitalized for heart failure in the United States : rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 : 209-216, 2005.
 
8) Nieminen MS, et al : EuroHeart Failure Survey II (EHFS II) : on hospitalized acute heart failure patients : description of population. Eur Heart J 27 : 2725-2736, 2006.
PubMed
9) Sato N, et al : Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77 : 944-951, 2013.
PubMed
10) Shiba N, et al : Analysis of chronic heart failure registry in the Tohoku district : third year follow-up. Circ J 68 : 427-434, 2004.
PubMed
11) Shiba N, et al : Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-first report from the CHART-2 study. Circ J 75 : 823-833, 2011.
PubMed
12) Tsuchihashi-Makaya M, et al : Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1893-1900, 2009.
PubMed
13) Jiang H, et al : Epidemiology and clinical management of cardiomyopathies and heart failure in China. Heart 95 : 1727-1731, 2009.
PubMed
14) Darnasceno A, et al : The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 172 : 1386-1394, 2012.
PubMed
15) Bocchi EA, et al : Cardiomyopathy, adult valve disease and heart failure in South America. Heart 95 : 181-189, 2009.
PubMed
P.343 掲載の参考文献
1) Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-327, 2013.
 
2) The Crlteria Committee of the New Ybrk Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th edition. Boston, Mass : Little & Brown ; 1994.
 
3) Madsen BK et al : Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J 15 : 303-310, 1994.
PubMed
4) Hunt SA, et al : 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 119 : e391-479, 2009.
 
5) Ammar KA et al : Prevalence and prognostic significance of heart failure stages : application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 115 : 1563-1570, 2007.
 
6) Heffer MA, et al : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 : 669-677, 1992.
 
7) The CONSENSUS Trial Study Group ; Effects of enalapril on mortality in severe congestive heart failure : results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
8) The SOLVD Investigators : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 : 685-691, 1992.
PubMed
9) Dargie HJ : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet 357 : 1385-1390, 2001.
PubMed
10) Vantrimpont B et al : Additive beneHcial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 29 : 229-236, 1997.
 
11) Pitt B, et al : Spironolactone for heart failure With preserved ejection fraction. N Engl J Med 370 : 1383-1392, 2014.
PubMed
12) Juurlink DN, et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 : 543-551, 2004.
PubMed
13) Bozkurt B, et al : Complications of inappropriate use of spironolactone in heart failure : when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41 : 211-214, 2003.
PubMed
14) McMurray JJ, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 : 993-1004, 2014.
PubMed
15) Mehra MR et al : Lisdng criteria for heart transplantadon : International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant 25 : 1024-1042, 2006.
PubMed
P.348 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告) 急性心不全治療ガイドライン (2011年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2011_izumi_h.pdf
 
2) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告) 慢性心不全治療ガイドライン (2010年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2010_matsuzaki_h.pdf
 
3) Poelzl G, et al : Cardiohepatic syndrome. Curr Heart Fail Rep 12 : 68-78, 2015.
PubMed
4) 佐久間由吉. うっ血性心不全による肝および血管病変の病理組織学的研究. 順天堂医学 27 (1) : 40-59, 1981.
 
5) Sandek A et al : Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50 : 1561-1569, 2007.
PubMed
6) Hirooka Y, et al : Endothelium-dependent forearm vasodilation to acetylcholine but not to substance Pis impaired in patients with heart failure. J Cardiovasc Pharmacol 20 : S221-225, 1992.
 
7) Zelis R, et al : Regional blood flow in congestive heart failure : concept of compensatory mechanisms with short and long time constants. Am J Cardiol 62 : 2E-8E, 1988.
 
8) Lipkin DP, et al : Abnormalities of skelet al muscle in patients with chronic heart failure. Int J Cardiol 18 : 187-195, 1988.
 
P.353 掲載の参考文献
1) McMurray JJ, et al : ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 : 1787-1847, 2012.
 
2) Stevenson LW, et al : The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261 : 884-888, 1989.
PubMed
3) Nohria A et al : Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 : 1797-1804, 2003.
PubMed
4) Kajimoto K, et al : Rapid evaluation by lung-cardiac-inferior vena cava (LCI) integrated ultrasound for differentiating heart failure from pulmonary disease as the cause of acute dyspnea in the emergency setting. Cardiovasc Ultrasound 10 : 49, 2012.
PubMed
5) Shah MR, et al : Impact of the pulmonary artery catheter in critically ill patients : meta-analysis of randomized clinical trials. JAMA 294 : 1664-1670, 2005.
PubMed
6) Sotomi Y, et al : Impact of pulmonary artery catheter on outcome in patients with acute heart failure syndromes with hypotension or receiving inotropes : from the ATTEND Registry. Int J Cardiol 72 : 65-172, 2014.
PubMed
P.358 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告). 慢性心不全治療ガイドライン (2010年改訂版). http://www.j-circ.or. jp/guideline/pdf/JCS2010_matsuzaki_h.pdf
 
2) Nohria A, et al : Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 : 1797-1804, 2003.
PubMed
3) 吉川純一 : 循環器フィジカル・イグザミネーションの実際 2005.
 
4) 日本心不全学会. 血中BNPやNT-proBNP値を用いた心不全診療の留意点について. http://www.asas.or.jp/jhfS/topics/bnp201300403.html
 
5) Okura H, et al : Noninvasive diagnosis of ischemic and nonischemic cardiomyopathy using coronary flow velocity measurements of the left anterior descending coronary artery by transthoracic Doppler echocardiography. J Am Soc Echocardiogr 19 : 552-558, 2006.
 
6) OkUra H, et al : Functional mitral regurgitation predicts prognosis independent of left ventricular systolic and diastolic indices in patients with ischemic heart disease. J Am Soc Echocardiogr 21 : 355-360, 2008.
PubMed
7) Rahman JE, et al : Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43 : 410-415, 2004.
PubMed
8) Motoki H, et al : Incremental prognostic value of assessing left ventricular myocardial mechanics in patients with chronic systolic heart failure. J Am Coll Cardiol 60 : 2074-2081, 2012.
PubMed
9) Nagueh SE et al : Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22 : 107-133, 2009.
 
10) Okura H, et al : Elevated E/E' predicts prognosis in congestive heart failure patients with preserved systolic function. Circ J 73 : 86-91, 2009.
 
11) Kraigher-Krainer E, et al : Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 63 : 447-456, 2014.
PubMed
12) Ueda T, et al : Left Ventricular Ejection Fraction (EF) of 55% as Cutoff for Late Transhion From Heart Failure (HF) With Preserved EF to HF With Mildly Reduced EF. Circ J 79 : 2209-2215, 2015.
PubMed
P.362 掲載の参考文献
1) 日本循環器学会 : 急性心不全治療ガイドライン (2011年改訂版)
 
2) Nieminen MS, et al : Executive summary of the guidelines on the diagnosis and treatment of acute heart failure : the task force on acute heart failure of the European Society of Cardiology. Eur Heart J 26 : 384-416, 2005.
 
3) 日本循環器学会 : 急性心不全治療ガイドライン (2006年改訂版)
 
4) Filippatos G, et al : An introduction to acute heart failure syndromes : definition and classMcation. Heart Fail Rev 12 : 87-90, 2007.
PubMed
5) Forrester JS, et al : Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med 295 : 1404-1413, 1976.
PubMed
6) Nohria A et al : Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 : 1797-1804, 2003.
PubMed
7) Peacock WF, et al : Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology 107 : 44-51, 2007.
PubMed
8) Mebaxaa A et al : Practical recommendations for prehospita1 and early in-hospita1 management of patients presenting with acute heart failure syndromes. Crit Care Med 36 : S129-139, 2008.
 
9) The CONSENSUS Trial Study Group : Effect of enalapril on motality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
10) The SOLVED Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 : 293-302, 1991.
 
11) Packer M, et al : Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1349-1355, 2001.
 
12) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-ID : a randomised trial. Lancet 353 : 9-13, 1999.
 
13) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
14) Piepoli MF, et al : Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 328 : 189, 2004.
PubMed
15) Taylor RS, et al : Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 4, 2014.
 
16) McAlister FA, et al : Multidisciplinary strategies for the management of heart failure patients at high risk for admission : asystematic review of randomized trials. J Am Coll Cardiol 44 : 810-819, 2004.
 
17) Martinez-Sell6s M, et al : End-stage heart disease in the elderly. Rev Esp Cardiol 62 : 409-421, 2009.
 
18) Goodlin SJ : Palliative care in congestive heart failure. J Am Coll Cardiol 54 : 386-396, 2009.
PubMed
P.367 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告). 慢性心不全治療ガイドライン (2010年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2010_matsuzaki_h.pdf
 
2) Jong R et al : Effect of enalapril on 12-year survival and life expectancy in patients with left vennicular systolic dysfunction : a follow-up study. Lancet 361 : 1843-1848, 2003.
 
3) Dargie HJ : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet 357 : 1385-1390, 2001.
PubMed
4) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
5) Tei C : Waon therapy : soothing warmth therapy. J Cardiol 49 : 301-304, 2007.
PubMed
P.371 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告), 急性心不全治療ガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_izumi_h.pdf
 
2) Mebazaa A, et al : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 : S129-139, 2008.
PubMed
3) Metra M, et al : Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure : a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 40 : 1248-1258, 2002.
PubMed
4) De Backer D, et al : Comparison of dopamine〔and norepinephrine in the treatment of shock. N Engl J Med 362 : 779-789, 2010.
 
5) Bock JS, et al : Cardiorenal syndrome : new perspectives. Circulation 121 : 2592-2600, 2010.
PubMed
6) Chen HH, et al : Low-dose dopamine or low-dose neshitide in acute heart failure With renal dysfunction : the ROSE acute heart failure randomized trial. JAMA 310 : 2533-2543, 2013.
 
7) O'Connor CM, et al : Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure : insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 : 78-86, 1999.
PubMed
8) Abraham WT, et al : In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications : an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46 : 57-64, 2005.
 
9) Cuffe MS, et al : Short-term intravenous milrinone for acute exacerbation of chronic heart failure : a randomized controlled trial. JAMA 287 : 1541-1547, 2002.
PubMed
10) Felker GM, et al : Heart failure etiology and response to milrinone in decompensated heart failure : results from the OPTIME-CHF study. J Am Coll Cardiol 41 : 997-1003, 2003.
PubMed
11) Sato N, et al : Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study : rationale, design, and preliminary data. Am Heart J 159 : 949-955. e1, 2010.
 
12) McMurray JJ, et al : ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 : The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 : 1787-1847, 2012.
 
P.375 掲載の参考文献
1) Hokimoto S, et al : Expression of angiotensin-converdng enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 94 : 1513-1518, 1996.
PubMed
2) Mizuno Y, et al : Aldosterone production is activated in failing ventricle in humans. Circulation 103 : 72-77, 2001.
PubMed
3) 慢性心不全治療ガイドライン (2010年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2010_matsuzaki_h.pdf
 
4) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 : 1429-1435, 1987.
 
5) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 327 : 685-691, 1992.
PubMed
6) Jong R et al : Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction : a follow-up study. Lancet 361 : 1843-1848, 2003.
 
7) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
8) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
9) Zannad E et al : Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 : 11-21, 2011.
 
10) Pitt B, et al : Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 : 1383-1392, 2014.
PubMed
11) McMurray JJ, et al : Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1 : 17-24, 2008.
PubMed
12) Solomon SD, et al : Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119 : 530-537, 2009.
 
13) Parving HH, et al : Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 : 2204-2213, 2012.
 
P.380 掲載の参考文献
1) Packer M, et al : Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
PubMed
2) Dargie HJ : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. Lancet 357 : 1385-1390, 2001.
PubMed
3) Colucci WS, et al : Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction : the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 116 : 49-56, 2007.
PubMed
4) Yoshikawa T, et al : Effectiveness of carvedilol alone versus carvedilol+pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group. Am J Cardiol 85 : 1495-1497 ; A7, 2000.
 
5) Bristow MR, et al : Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94 : 2807-2816, 1996.
PubMed
6) Fiuzat M, et al : Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction : Results From the HF-ACTION Trial. JACC Heart Fail 4 : 109-115, 2016.
 
7) Bello D, et al : Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 108 : 1945-1953, 2003.
PubMed
8) Kotecha D, et al : Efficacy of β blockers in patients with heart failure plus atrial fibrillation : an individualpatient data meta-analysis. Lancet 384 : 2235-2243, 2014.
 
9) Kumar A et al : Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 142 : 512-515, 2001.
PubMed
10) Gattis WA, et al : Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure : results of the Initiation Management Predischarge : Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 43 : 1534-1541, 2004.
 
11) Edelmann E et al : Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF : Insights From the CIBIS-ELD Trial. JACC Heart Fail 4 : 140-149, 2016.
 
12) Jondeau G, et al : B-CONVINCED : Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 30 : 2186-2192, 2009.
PubMed
13) Yancy CW, et al : Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function : a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47 : 76-84, 2006.
 
14) Nagai R, et al : Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction : comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin U-Land Study). Circ J 77 : 908-916, 2013.
 
15) Kobayashi S, et al : Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J 76 : 1646-1653, 2012.
 
P.386 掲載の参考文献
1) Mebazaa A, et al : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 : S129-139, 2008.
PubMed
2) Cotter G, et al : Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351 : 389-393, 1998.
PubMed
3) Taira N, et al : Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75). Clin Exp Pharmacol Physiol 6 : 301-316, 1979.
PubMed
4) Zhao E et al : Effect of nicorandil in patients with heart failure : asystematic review and meta-analysis. Cardiovasc Ther 32 : 283-296, 2014.
 
5) Taylor AL, et al : Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine : consistency across subgroups in the African-American Heart Failure Trial. Circulation 115 : 1747-1753, 2007.
PubMed
6) Packer M, et al : Prognostic importance of the immediate hemodynamic response to nifedipine in padents with severe left ventricular dysfunction. J Am Coll Cardiol 10 : 1303-1311, 1987.
 
7) Elkayam U, et al : A prospective, randomized, double-blind, crossover study to compare the efncacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 82 : 1954-1961, 1990.
PubMed
8) Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II) Am J Cardiol 66 : 779-785, 1990.
PubMed
9) The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 319 : 385-392, 1988.
 
10) Figulla HR, et al : Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 94 : 346-352, 1996.
PubMed
11) Packer M, et al : Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evalution Study Group. N Engl J Med 335 : 1107-1114, 1996.
 
12) O'Connor CM, et al : Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation, Am J Cardiol 82 : 881-887, 1998.
PubMed
13) Udelson JE, et al : Effects of amlodipine on exercise tolerance, quanty of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am Heart J 139 : 503-510, 2000.
 
14) Hata N, et al : Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure : the PROTECT multicenter randomized controlled study. Circ J 72 : 1787-1793, 2008.
 
15) Kajimoto K et al : Systolic blood pressure at admission as a predictor of the response to initial carperitide therapy in patients hospitalized for acute decompensated heart failure with left ventricular systolic dysfunction. Cardiovasc Drugs Ther 23 : 481-488, 2009.
PubMed
16) Kitakaze M, et al : Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND) : two randomised trials. Lancet 370 : 1483-1493, 2007.
PubMed
17) O'Connor CM, et al : Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 : 32-43, 2011.
PubMed
18) Bojun G, et al : EfficaCy and safety of nesiritide in patients With decompensated heart failure : a meta-analysis of randomized trial. BMI Open 6 : e008545, 2016.
 
P.390 掲載の参考文献
1) Mentz RJ, et al : Decongestion in acute heart failure. Eur J Heart Fail 16 : 471-482, 2014.
PubMed
2) Felker GM, et al : Loop diuretics in acute decompensated heart failure : necessary? Evil? A necessary evil? Circ Heart Fail 2 : 56-62, 2009.
PubMed
3) Felker GM, et al : Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364 : 797-805, 2011.
PubMed
4) Buckley LF, et al : Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Fail 4 : 1-8, 2016.
 
5) Damman K, et al : Loop diuretics, renal function and clinical outcome in patients With heart failure and reduced ejection fraction. Eur J Heart Fail 18 : 328-336, 2015.
PubMed
6) McCurley JM, et al : Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 44 : 1301-1307, 2004.
PubMed
7) Yoshida J, et al : Different effects of long-and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. Cardiovasc Res 68 : 118-127, 2005.
PubMed
8) Hisatake S, et al : Comparative analysis of the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic heart failure using (123) I-metaiodobenzylguanidine scintigraphy. Eur J Heart Fail 13 : 892-898, 2011.
PubMed
9) Masuyama T, et al : Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J 76 : 833-842, 2012.
PubMed
P.394 掲載の参考文献
1) Ahmed A et al : Heart failure, chronic diuretic use, and increase in mortality and hospitalizadon : an observational study using propensity score methods. Eur Heart J 27 : 1431-1439, 2006.
PubMed
2) Abdel-Qadir HM, et al : Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 160 : 264-271. e 1, 2010.
 
3) Matsuzaki M, et al : Efficacy and safety of tolvaptan in heart failure padents with volume overload despite the standard treatment with conventional diuretics ; a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25 Suppl 1 : S33-45, 2011.
 
4) Gheorghiade M, et al : Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : the EVEREST Clinical Status Trials. JAMA 297 : 1332-1343, 2007.
PubMed
5) Kinugawa K, et al : Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circulation J 78 : 844-852, 2014.
 
6) 内田英二, ほか : トルバプタンの至適投与法の検討, p71-74, 診療と新薬, 2013.
 
7) Takimura H, et al : Efficacy and safety of coadministration of tolvaptan and carperitide for acute decompensated heart failure patients. J Clin Exp Cardiolog 2015.
 
8) Matsue Y, et al : Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 61 : 169-174, 2013.
PubMed
9) Suzuki S, et al : Acute heart failure volume control multicenter randomized (AVCMA) trial : comparison of tolvaptan and carperitide. J Clin Pharmacol 53 : 1277-1285, 2013.
PubMed
10) Forman DE, et al : Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43 : 61-67, 2004.
PubMed
11) Shirakabe A et al : Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 78 : 911-921, 2014.
PubMed
12) Konstam MA et al : Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA 297 : 1319-1331, 2007.
PubMed
13) Ambrosy A et al : Tolvaptan for the treatment of heart failure : areview of the literature. Expert Opin Pharmacother 12 : 961-976, 2001.
 
14) Hauptman PJ, et al : Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 19 : 390-397, 2013.
 
P.399 掲載の参考文献
1) Fevold HL, et al : The relaxative hormone of the corpus luterum. Its purification and concentration. J Am Chem Soc 52 : 3340-3348, 1930.
 
2) Samuel CS, et al : Relaxin in cardiovascular and renal disease. Kidney Int 69 : 1498-1502, 2006.
PubMed
3) Du XJ, et al : Therapeutic effects of serelaxin in acute heart failure. Circ J 78 : 542-552, 2014.
PubMed
4) Teichman SL, et al : Relaxin : review of biology and potential role in treating heart failure. Curr Heart Fail Rep 7 : 75-82, 2010.
PubMed
5) Teerlink JR, et al : Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF) : a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373 : 1429-1439, 2009.
PubMed
6) Sato N, et al : Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. Circ J 79 : 1237-1247, 2015.
PubMed
7) Dahlke M, et al : Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations. J Clin Pharmacol 55 : 415-422, 2015.
 
8) Teerlink JR et al : Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF) : a randomised, placebo-controlled trial. Lancet 381 : 29-39, 2013.
PubMed
9) Ponikowski P, et al : A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 35 : 431-441, 2014.
PubMed
10) Metra M, et al : Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program : correlation with outcomes. J Am Coll Cardiol 61 : 196-206, 2013.
PubMed
11) Voors AA, et al : Early drop in systolic blood pressure and worsening renal function in acute heart failure : renal results of Pre-RELAX-AHE Eur J Heart Fail 13 : 961-967, 2011.
 
P.406 掲載の参考文献
1) Brush S, et al : Palliative care for the patient with end-stage heart failure. Prog Cardiovasc Nurs 21 : 166-170, 2006.
PubMed
2) Hunt SA et al : ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation : endorsed by the Heart Rhythm Society. Circulation 112 : e154-235, 2005.
 
3) Mulder R et al : Long-term heart rate reduction induced by the selective I (f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109 : 1674-1679, 2004.
 
4) Swedberg K et al : Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebocontrolled study. Lancet 376 : 875-885, 2010.
PubMed
5) Bohm M, et al : Heart rate as a risk factor in chronic heart failure (SHIFT) : the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376 : 886-894, 2010.
 
6) Reil JC, et al : Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 62 : 1977-1985, 2013.
PubMed
7) Santos M, et al : Ef飴ct of ivabradine on heart failure with preserved ejection fraction. J Am Coll Cardiol 63 : 608-609, 2014.
 
8) Kostis JB, et al : Omapatrilat and enalapril in patients with hypertension : the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17 : 103-111, 2004.
PubMed
9) Packer M, et al : Comparison of omapatrilat and enalapril in patients with chronic heart failure : the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 : 920-926, 2002.
PubMed
10) Vardeny O, et al : First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther 94 : 445-448, 2013.
PubMed
11) McMurray J, et al : A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J 36 : 434-439, 2015.
 
12) Neprilysin lnhibition for Heart Failure. N Engl J Med Neprilysin Inhibition for Heart Failure. N Engl J Med 371 : 2335-2337, 2014.
 
13) Solomon SD, et al : The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction : a phase 2 double-blind randomised controlled trial. Lancet 380 : 1387-1395, 2012.
PubMed
P.410 掲載の参考文献
1) Dunlay SM, et al : Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 5 : 720-726, 2012.
PubMed
2) Yamamoto K, et al : Heart failure with preserved ejection fraction-what is known and unknown. Circ J 73 : 404-410, 2009.
PubMed
3) Edelmann F, et al : Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol 100 : 755-764, 2011.
PubMed
4) Zile MR, et al : Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 : 1953-1959, 2004.
PubMed
5) Takeda Y, et al : Competing risks of heart failure with preserved ejection fraction in diabetic patients. Eur J Heart Fail 13 : 664-669, 2011.
PubMed
6) Yamamoto K et al : Relation of risk factors with response to carvedilol in heart failure with preserved election fraction-a report from the Japanese Diastolic Heart Failure Study (J-DHF). J Cardiol 63 : 424-431, 2014.
 
7) Kao D R et al : Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail 17 : 925-935, 2015.
 
8) Kinugasa Y, et al : A simple risk score to predict in-hospital death of elderly patients with acute decompensated heart failure-hypoalbuminemia as an additional prognostic factor. Circ J 73 : 2276-2281, 2009.
PubMed
9) Kinugasa Y et al : Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fracdon. Circ J 77 : 705-711, 2013.
PubMed
10) Omori Y, et al : LCarnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 30 : 1834-1844, 2012.
PubMed
11) Taylor RS, et al : Effects of exercise training for heart failure with preserved ejection fraction : a systematic review and meta-analysis of comparative studies. Int J Cardiol 162 : 6-13, 2012.
PubMed
12) Ktzman DW, et al : Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved election fraction : a randomized, controlled, singleblind trial. J Am Coll Cardiol 62 : 584-592, 2013.
 
13) Yamada K et al : lnspiratory Muscle Weakness is Associated With Exercise lntolerance in Patients With Heart Failure with Preserved Ejection Fraction : a Preliminary Study. J Card Fail 22 : 38-47, 2016.
PubMed
14) Bowen TS, et al : Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skelet al muscle. Eur J Heart Fail 17 : 263-272, 2015.
 
15) Yamamoto K : β-Blocker therapy in heart failure with preserved ejection fraction : Importance of dose and duration. J Cardiol 66 : 189-194, 2015.
 
P.417 掲載の参考文献
1) 日本臨床補助人工心臓研究会「植込型補助人工心臓」実施基準 (2010. 11. 16案)
 
2) Stevenson LW, et al : INTERMACS profiles of advanced heart failure : the current picture. J Heart Lung Transplant 28 : 535-541, 2009.
PubMed
3) Kirk lin JK et al : The Fourth INTERMACS Annual Report : 4,000 implants and counting. J Heart Lung Transplant 31 : 117-126, 2012.
 
P.422 掲載の参考文献
1) Moss AJ, et al : Prophylactic implantation of a defibrillator in patients With myocardial infarction and reduced ejection fraction. N Engl J Med 346 : 877-883, 2002.
PubMed
2) Kadish A et al : Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 : 2151-2158, 2004.
PubMed
3) Bardy GH, et al : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 : 225-237, 2005.
 
4) Tanno K et al : Are the MADIT II criteria for ICD implantation appropriate for Japanese patients? Circ J 69 : 19-22, 2005.
 
5) Satake H, et al : Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure-a report from the CHART-2 Study. Circ J 79 : 381-390, 2015.
PubMed
6) Cleland JG, et al : The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 : 1539-1549, 2005.
PubMed
7) Wikstrom G, et al : The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J 30 : 782-788, 2009.
PubMed
8) Ypenburg C, et al : Impact of viabihty and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. Eur Heart J 28 : 33-41, 2007.
PubMed
9) Ypenburg C, et al : Effect of total scar burden on contrast-enhanced magnetic resonance imaging on response to cardiac resynchronization therapy. Am J Cardiol 99 : 657-660, 2007.
PubMed
10) Scirica BM, et al : Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death : observations from the metabolic efHciency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarcdon 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 122 : 455-462, 2010.
 
11) Moss AJ, et al : Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361 : 1329-1338, 2009.
PubMed
12) Tang AS, et al : Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363 : 2385-2395, 2010.
PubMed
P.425 掲載の参考文献
1) Shiba N, et al : Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-first report from the CHART-2 study. Circ J 75 : 823-833, 2011.
PubMed
2) Okura Y, et al : Impending epidemic : future projection of heart failure in Japan to the year 2055. Circ J 72 : 489-91, 2008.
 
3) Takii T et al : Trends in acute myocardial infarction incidence and mortality over 30 years in Japan : report from the MIYAGI-AMI Registry Study. Circ J 74 : 93-100, 2010.
PubMed
4) Bradley TD, et al : Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 : 2025-2033, 2005.
PubMed
5) Kasai T et al : Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail 3 : 140-148, 2010.
PubMed
6) Cowie MR et al : Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 373 : 1095-1105, 2015.
PubMed
7) Momomura S, et al : Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J 79 : 981-990, 2015.
 
8) Mehra R, et al : Sleep apnea in acute coronary syndrome : high prevalence but low impact on 6-month outcome. Sleep Med 7 : 521-528, 2006.
PubMed
9) Lee CH, et al : Obstructive sleep apnea in patients admitted for acute myocardial infarction. Prevalence, predictors, and effect on microvascular perfusion. Chest 135 : 1488-1495, 2009.
PubMed
10) Ludka O, et al : Sleep apnea prevalence in acute myocardial infarction-the Sleep Apnea in Post-acute Myocardial Infarction Patients (SAPAMI) Study. Int J Cardiol 176 : 13-19, 2014.
PubMed
11) Nakashima H, et al : 0bstructive sleep apnoea inhibits the recovery of left ventricular function in patients with acute myocardial infarction. Eur Heart J 27 : 2317-2322, 2006.
PubMed
12) Yumino D, et al : Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol 99 : 26-30, 2007.
PubMed
13) Buchner S, et al : Impact of sleep-disordered breathing on myocardial salvage and infarct size in patients with acute myocardial infarction. Eur Heart J 35 : 192-199, 2014.
PubMed
14) Gray A, et al : Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 359 : 142-151, 2008.
PubMed
15) Mooe T et al : Sleep-disordered breathing in men with coronary artery disease. Chest 109 : 659-663, 1996.
PubMed
16) Schafer H, et al : Obstructive sleep apnea as a risk marker in coronary artery disease. Cardiology 92 : 79-84, 1999.
PubMed
17) Inami T, et al : Ijnks between sleep disordered breathing, coronary atherosclerotic burden, and cardiac biomarkers in patients with stable coronary artery disease. J Cardiol 60 : 180-186, 2012.
PubMed
18) Tan A et al : OSA and coronary plaque characteristics. Chest 145 : 322-330, 2014.
PubMed
19) Garcia-Rio F : Recurrent acute myocardial infarction and CPAP effect in mild-severe OSA : is an independent risk factorP Int J Cardiol 171 : e19, 2014.
 
20) Milleron O, et al : Benefits of obstructive sleep apnoea treatment in coronary artery disease : a long-term follow-up study. Eur Heart J 25 : 728-734, 2004.
PubMed
21) Marin JM, et al : Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure : an observational study Lancet 365 : 1046-1053, 2005.
PubMed
22) Peled N, et al : Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease : effects of continuous positive air pressure treatment. J Am Coll Cardiol 34 : 1744-1749, 1999.
PubMed
P.431 掲載の参考文献
1) 日本循環器学会循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告), 慢性心不全治療ガイドライン (2010年改訂版). http://www.j-circr.jp/guideline/pdf/JCS2010_matsuzaki_h.pdf
 
2) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 33 : 1787-1847, 2012.
PubMed
3) Costanzo MR, et al : Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49 : 675-683, 2007.
PubMed
4) Bart BA et al : Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367 : 2296-2304, 2012.
PubMed
5) 竹内利治, ほか : 心不全に対する血液浄化療法-積極的な立場から. Fluid Management Renaissance 5 : 78-81, 2015
 
6) Marenzi G, et al : Continuous ultraf｝ltration for congestive heart failure : the CUORE trial. J Card Fail 20 : 9-17, 2014.
 
7) Braunwald E : Biomarkers in heart failure. N Engl J Med 358 : 2148-2159, 2008.
PubMed
8) VA/NIH Acute Renal Failure Trial Network, et al : Intensity of renal support in critically in patients with acute kidney injury. N Engl J Med 359 : 7-20, 2008.
PubMed
9) RENAL Replacement Therapy Study Investigators, et al : Intensity of continuous renal-replacement therapy in critically in patients. N Engl J Med 361 : 1627-1638, 2009.
 
10) Uchino S, et al : Continuous renal replacement therapy : a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B. E. S. T. kidney) investigators. Intensive Care Med 33 : 1563-1570, 2007.
 
11) Uchino S, et al : Discontinuation of continuous renal replacement therapy : a post hoc analysis of a prospective multicenter observational study. Crit Care Med 37 : 2576-2582, 2009.
PubMed
P.436 掲載の参考文献
1) WHO : 緩和ケアの定義 (2002). http://www.who.int/cancer/palliative/definition/en/
 
2) プラハ憲章 (2013). http://www.eapcnet.eu/Themes/Policy/PragueCharter.aspx
 
3) Yancy CW, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 : e147-239, 2013.
 
4) Murray SA, et al : Illness trajectories and palliative care. BMJ 330 : 1007-1011, 2005.
PubMed
5) Allen LA et al : Decision maldng in advanced heart failure : a scientific statement from the American Heart Association. Circulation 125 : 1928-1952, 2012.
PubMed
6) Small N, et al : Using a prediction of death in the next 12 months as a prompt for referral to palliative care acts to the detriment of patients with heart failure and chronic obstructive pulmonary disease. Palliat Med 24 : 740-741, 2010.
 
7) Goodlin SJ, et al : Communication and decision-making about prognosis in heart failure care. J Card Fail 14 : 106-113, 2008.
 
8) 能芝範子 : 心不全診療におけるコミュニケーション. 心不全の緩和ケア (大石醒悟ほか編), 南山堂, p113-129, 2014.
 
9) 大石醒悟, 高田弥寿子 : 末期心不全の症状緩和. 心不全の緩和ケア (大石醒悟ほか編), 南山堂, p63-89, 2014.
 
10) 苦痛緩和のための鎮静に関するガイドライン2010年度版日本緩和医療学会 : https://www.jspm.ne.jp/guidelines/sedation/2010/index.php
 
P.440 掲載の参考文献
1) Shimizu T, et al : Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ Res 90 : e40, 2002.
PubMed
2) Shimizu T, et al : Electrically communicating three-dimensional cardiac tissue mimic fabricated by layered cultured cardiomyocyte sheets. J Biomed Mater Res 60 : 110-117, 2002.
 
3) Miyagawa S, et al : Tissue cardiomyoplasty using bioengineered contractile cardiomyocyte sheets to repair damaged myocardium : their integration with recipient myocardium. Transplantation 80 : 1586-1595, 2005.
PubMed
4) Memon IA, et al : Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg 130 : 1333-1341, 2005.
 
5) Kondoh H, et al : Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters. Cardiovasc Res 69 : 466-475, 2006.
PubMed
6) Hata H, et al : Grafted skelet al myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model. J Thorac Cardiovasc Surg 132 : 918-924, 2006.
 
7) Miyagawa S, et al : Impaired myocardium regeneration with skelet al cell sheets-a preclinical trial for tissue-engineered regeneration therapy. Transplantation 90 : 364-372, 2010.
 
8) Sawa Y, et al : Safety and Efficacy of Autologous Skelet al Myoblast Sheets (TCD-51073) for the Treatment of Severe Chronic Heart Failure Due to Ischemic Heart Disease. Circ J 79 : 991-999, 2015.
 
9) Imamura T, et al : Improved clinical course of autologous skelet al myoblast sheet (TCD-51073) transplantation when compared to a propensity score-matched cardiac resynchronization therapy population. J Artif Organs 19 : 80-86, 2016.
 
P.446 掲載の参考文献
1) Nakatani T, et al : The registry report of heart transplantation in Japan (1999-2013). Circ J 78 : 2604-2609, 2014.
PubMed
2) Fukushima N, et al : Heart donation in Japan before and after the revision of the Japanese Transplantation Act. Transplant Proc 46 : 2050-2053, 2014.
PubMed
3) Nakatani T, et al : The Registry Report of Heart Transplantation in Japan (1999-2014). Circ J 80 ; 44-50, 2016.
PubMed
4) 池晶子, ほか : 生物工学基礎講座 バイオよもやま話. 生物工学 89 : 194, 2011.
 
5) Kijpittayarit, Arthurs S, et al : Clinical featUres and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant 26 : 1019-1024, 2007.
PubMed
6) Garcia VD, et al : RitUximab and rapamycin for posttransplant lymphoproliferative disease treatment : report of three cases. Transplant Proc 34 : 2993-2995, 2002.
PubMed
7) Yamasaki M, et al : Impact of donor-transmitted atherosclerosis on early cardiac allograft vasculopathy : new findings by three-dimensional intravascular ultrasound analysis. Transplantation 91 : 1406-1411, 2011.
PubMed
8) Braga JR, et al : Factors associated With the development of cardiac allograft vasculopathy-a systematic review of observational studies. Clin Transplant 26 : E111-124, 2012.
PubMed
9) Radovancevic B, et al : Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Sur 4 : 309-312, 1990.
 
10) Sanchez Lazaro U, et al lnfluenoe of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation. Transplant Proc 40 : 3056-3057, 2008.
 
11) Halle AA, et al : Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 26 : 120-128, 1995.
PubMed
12) 熊坂礼音, ほか : 2012年第16回日本心不全学会学術集会.
 
P.451 掲載の参考文献
1) 心房細動治療 (薬物) ガイドライン (2008年改訂版). Circ J 72 : 158-1638, 2008.
 
2) Sato N, et al : Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study : rationale, design, and preliminary data. Am Heart J 159 : 949-955. e1, 2010.
 
3) Benjamin EJ, et al : Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 : 840-844, 1994.
 
4) de Vos CB, et al : Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 55 : 725-731, 2010.
PubMed
5) Wang TJ, et al : Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality : the Framingham Heart Study. Circulation 107 : 2920-2925, 2003.
PubMed
6) Pozzoli M, et al : Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure : aprospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 32 : 197-204, 1998.
 
7) Roy D, et al : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 : 2667-2677, 2008.
PubMed
8) Deedwania PC, et al : Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation : observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98 : 2574-2579, 1998.
PubMed
9) Khan MN, et al : Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359 : 1778-1785, 2008.
PubMed
10) Jones DG, et al : A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 61 : 1894-1903, 2013.
PubMed
11) Marrouche NF, et al : Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF) -study design. Pacing Clin Electrophysiol 32 : 987-994, 2009.
PubMed
12) Rienstra M, et al : Beta-blockers and outcome in heart failure and atrial fibrillation : a meta-analysis. JACC Heart Fail 1 : 21-28, 2013.
PubMed
13) Turakhia MR et al : Increased mortality associated with digoxin in contemporary patients with atrial fibrillation : findings from the TREAr-AF study. J Am Coll Cardiol 64 : 660-668, 2014.
 
14) Whitbeck MG, et al : Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J 34 : 1481-1488, 2013.
PubMed
15) Fauchier L, et al : Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 103 : 248-254, 2009.
PubMed
16) Van Gelder IC, et al : Lenient versus strict rate control in patients With atrial fibrillation. N Engl J Med 362 : 1363-1373, 2010.
PubMed
17) Li SJ, et al : Prognostic Significance of Resting Heart Rate and Use of 3-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction : Findings From the Swedish Heart Failure Registry. Circ Heart Fail 8 : 871-879, 2015.
 
P.456 掲載の参考文献
1) 百村伸一, ほか : 循環器病の診断と治療に関するガイドライン (2008-2009年度合同研究班報告) 【ダイジェスト版】循環器領域における睡眠呼吸障害の診断・治療に関するガイドライン. Circ J 74 : 1053-1084, 2010.
 
2) Somers VK, et al : Sleep apnea and cardiovascular disease : an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National InstitUtes of Health). Circulation 118 : 1080-1111, 2008.
 
3) Marin JM, et al : Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure : an observational study. Lancet 365 : 1046-1053, 2005.
PubMed
4) Gottlieb DJ, et al : Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure : the sleep heart health study. Circulation 122 : 352-360, 2010.
PubMed
5) Tan. A, et al : OSA and coronary plaque characteristics. Chest 145 : 322-330, 2014.
PubMed
6) Kuniyoshi FH, et al : Day-night variation of acute myocardial infarction in obstructive sleep apnea. J Am Coll Cardiol 52 : 343-346, 2008.
PubMed
7) Buchner S, et al : Impact of sleepdisordered breathig on myocardial salvage and infarct size in patients with acute myocardial infarction. Eur Heart J 35 : 192-199, 2014.
PubMed
8) Garcia-Rio E et al : CPAP effect on recurrent episodes in patients with sleep apnea and myocardial infarction. Int J Cardiol 168 : 1328-1335, 2013.
 
9) Oldenburg O, et al : Sleepdisordered breathing in patients with symptomatic heart failure : a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail 9 : 251-257, 2007.
PubMed
10) Sin DD, et al : Risk factors for central and obstructive sleep apnea in 450 men and women With congestive heart failure. Am J Respir Crit Care Med 160 : 1101-1106, 1999.
PubMed
11) Ferrier K, et al : Sleep-disordered breathing occurs frequently in stable outpatients with congestive heart failure. Chest 128 : 2116-2122, 2005.
PubMed
12) Lanfranchi PA, et al : Prognosdc value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 99 : 1435-1440, 1999.
PubMed
13) Javaheri S, et al : Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 97 : 2154-2159, 1998.
PubMed
14) Yumino D, et al : Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction. J Card Fail 15 : 279-285, 2009.
PubMed
15) Bitter T, et al : Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 11 : 602-608, 2009.
PubMed
16) Herrscher TE, et al : High prevalence of sleep apnea in heart failure outpatients : even in patients with preserved systolic function. J Card Fail 17 : 420-425, 2011.
PubMed
17) Mortara A et al : Association betWeen hemodynamic impairment and Cheyne-Stokes respiration and periodic breathing in chronic stable congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 84 : 900-904, 1999.
PubMed
18) Yumino D, et al : Nocturnal rostral fluid shift : a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 121 : 1598-1605, 2010.
PubMed
19) Javaheri S, et al : Sleep apnea testing and outcomes in a large cohort of Medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med 183 : 539-546, 2011.
 
20) Kasai T, et al : Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. Chest 133 : 690-696, 2008.
PubMed
21) Bradley TD, et al : Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 353 : 2025-2033, 2005.
PubMed
22) Arzt M, et al : Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure : a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 115 : 3173-3180, 2007.
PubMed
23) Teschler H, et al : Adaptive pressure support servo-ventilation : anovel treatment for Cheyne-Stokes respiration in heart failure. Am J Respir Crit Care Med 164 : 614-619, 2001.
 
24) Oldenburg O, et al : Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration. Eur J Heart Fail 10 : 581-586, 2008.
PubMed
25) Kasai T, et al : Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail 3 : 140-148, 2010.
PubMed
26) Kasai T, et al : Adaptive servo-ventilation in cardiac function and neurohormonal status in patients with heart failure and central sleep apnea nonresponsive to continuous positive airway pressure. JACC Heart Fail 1 : 58-63, 2013.
PubMed
27) Owada T, et al : Adaptive servoventilation improves cardiorenal function and prognosis in heart failure patients with chronic kidney disease and sleepdisordered breathing. J Card Fail 19 : 225-232, 2013.
 
28) Miyata M, et al : Adaptive servo ventilation improves Cheyne-Stokes respiration, cardiac function, and prognosis in chronic heart failure patients with cardiac resynchronization therapy. J Cardiol 60 : 222-227, 2012.
PubMed
29) Takama N, et al : Safety and efficacy of adaptive servo-ventilation in patients with severe systolic heart failure. J Cardiol 63 : 302-307, 2014.
PubMed
30) Nakamura S, et al : Impact of sleep-disordered breathing and efficacy of positive airway pressure on mortality in patients with chronic heart failure and sleep-disordered breathing : a meta-analysis. Clin Res Cardiol 104 : 208-216, 2015.
PubMed
31) Cowie MR, et al : Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med 373 : 1095-1105, 2015.
PubMed
32) Yamauchi M, et al : Adaptive Servo-Ventilation for Central Sleep Apnea in Heart Failure. N Engl J Med 374 : 689, 2016.
PubMed
33) Oldenburg O, et al : Heart failure : Central sleep apnoea in HF-what can we learn from SERVE-HF? Nat Rev Cardiol 12 : 686-687, 2015.
PubMed
34) Bradley TD, et al : The SERVE-HF Trial. Can Respir J 22 : 313, 2015.
PubMed
35) Momomura S, et al : Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J 79 : 981-990, 2015.
 
36) 心不全症例におけるASV適正使用に関するステートメント (第1報) -SERVE-HF試験のプレス発表を受けて-http://www.j-circ.or.jp/information/ASV_tekiseiriyou.pdf
 
37) Bitter T, et al : Adaptive servoventilation in diastolic heart failure and Cheyne-Stokes respiration. Eur Respir J 36 : 385-392, 2010.
PubMed
38) Yoshihisa A et al : Impact of adaptive servo-ventilation on cardiovascular function and prognosis in heart failure patients with preserved left ventricular ejection fraction and sleep-disordered breathing. Eur J Heart Fail 15 : 543-550, 2013.
PubMed
39) Yoshihisa A et al : Beneficial Effects of Positive Airway Pressure Therapy for Sleep-Disordered Breathing in Heart Failure Patients With Preserved Left ventricular Ejection Fraction. Clin Cardiol 38 : 413-421, 2015.
PubMed
P.462 掲載の参考文献
1) Okura Y, et al : Impending epidemic : future projection of heart failure in Japan to the year 2055. Circ J 72 : 489-491, 2008.
 
2) COPDに関する統計資料, COPD情報サイト, GOLD日本委員会 (http://www.gold-jac.jp/copd_facts_in_japan/).
 
3) 日本呼吸器学会COPDガイドライン第4版作成委員会編 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第4版. 東京, メディカルレビュー社, 2013.
 
4) Fukuchi Y, et al : COPD in Japan : the Nippon COPD Epidemiology study. Respirology 9 : 458-465, 2004.
PubMed
5) Nishimura K, et al : Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 9 : 155-162, 2014.
PubMed
6) Hawkins NM, et al : Heart failure and chronic obstructive pulmonary disease : the challenges facing physicians and health services. Eur Heart J 34 : 2795-2803, 2013.
PubMed
7) Yoshihisa A et al : Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol 64 : 256-264, 2014.
PubMed
8) Curkendall SM, et al : Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 16 : 63-70, 2006.
PubMed
9) Rutten FH, et al : Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 26 : 1887-1894, 2005.
PubMed
10) Le Jemtel TH, et al : Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 49 : 171-180, 2007.
PubMed
11) Yamauchi Y, et al : Paradoxical association between body mass index and in-hospital mortality in elderly patients with chronic obstructive pulmonary disease in Japan. Int J Chron Obstruct Pulmon Dis 9 : 1337-1346, 2014.
PubMed
12) Takiguchi M, et al : Impact of body mass index on mortality in heart failure patients. Eur J Clin Invest 44 : 1197-1205, 2014.
PubMed
13) Gosker HR, et al : Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest 123 : 1416-1424, 2003.
PubMed
14) Tashkin DP, et al : A 4 year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 : 1543-1554, 2008.
PubMed
15) Kubota Y, et al : impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 10 : 515-523, 2015.
 
P.468 掲載の参考文献
1) ガイドライン改訂委員会 : 日核. 高尿酸血症・痛風の治療ガイドライン第2版2010, メディカルレビュー社, 東京, 2010.
 
2) Ichida K, et al : Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3 : 764, 2012.
PubMed
3) Kuwabara M : Review ; Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse (Basel) 3 : 242-252, 2015.
 
4) Hamaguchi S, et al : Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151 : 143-147, 2011.
PubMed
5) Ross EA, et al : Renal function and urate metabolism in late survivors with cyanotic congenital heart disease. Circulation 73 : 396-400, 1986.
PubMed
6) Givertz MM, et al : Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients : The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation 131 : 1763-1771, 2015.
 
7) Kojima S, et al : Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol, 2016.
PubMed
8) Anker SD, et al : Uric acid and survival in chronic heart failure : validation and application in metabolic, functional, and hemodynamic staging. Circulation 107 : 1991-1997, 2003.
PubMed
9) Kojima S, et al : Prognostic usefUlness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 96 : 489-495, 2005.
PubMed
10) Krishnan E : Hyperuricemia and incident heart failure. Circ Heart Fail 2 : 556-562, 2009.
PubMed
11) Shimizu T, et al : Relationship of hyperuricemia With mortality in heart failure patients With preserved ejection fraction. Am J Physiol Heart Circ Physiol 309 : H1123-1129, 2015.
PubMed
12) Chen CC, et al : Impact of elevated uric acid on ventricular remodelmg in infarcted ratS With experimental hyperuricemia. Am J Physiol Heart Circ Physiol 301 : H1107-1117, 2011.
PubMed
13) Yang Q, et al : Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 3 : 523-530, 2010.
PubMed
14) Nakagomi A, et al : Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia. IJC Metab Endocr 8 : 46-55, 2015.
 
15) Konstam MA, et al : Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study) : a randomised, double-blind trial. Lancet 374 : 1840-1848, 2009.
PubMed
16) Kang SM, et al : High-dose versus low-dose losartan in patients with heart failure. Lancet 375 : 1079 ; author reply 1079-1080, 2010.
PubMed
17) Ogino K et al : Uric acid-lowering treatment with benzbromarone in patients with heart制ure : a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 3 : 73-81, 2010.
 
18) Goicoechea M, et al : Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5 : 1388-1393, 2010.
PubMed
19) Noman A. et al : Effect of high-dose allopurinol on exercise in patients with chronic stable angina : a randomised, placebo controlled crossover trial. Lancet 375 : 2161-2167, 2010.
PubMed
20) Erdogan D, et al : Effects of allopurinol on coronary microvascular and left ventricular function in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 28 : 721-727, 2012.
PubMed
P.472 掲載の参考文献
1) Emerging Risk Factors Collaboration, et al : Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med 364 : 829-841, 2011.
PubMed
2) Kannel WB, et al : Diabetes and cardiovascular disease. The Framingham study. JAMA 241 : 2035-2038, 1979.
PubMed
3) Kannel WB, et al : Diabetes and glucose tolerance as risk factors for cardiovascular disease : the Framingham study. Diabetes Care 2 : 120-126, 1979.
PubMed
4) Yancy CW, et al : Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 344 : 1358-1365, 2001.
PubMed
5) Cohn JN, et al : Arandomized tHal of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
 
6) Authors/Task Force Members, et al : ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD : the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 : 3035-3087, 2013.
 
7) Bando YK, et al : Diabetes-related heart failure. Circ J 78 : 576-583, 2014.
PubMed
8) Rijzewijk LJ, et al : Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 52 : 1793-1799, 2008.
PubMed
9) Hammer S, et al : Prolonged caloric restriction in obese patients with type 2 diabetes mellitUs decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 52 : 1006-1012, 2008.
PubMed
10) Monji A, et al : Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol 305 : H295-304, 2013.
PubMed
P.476 掲載の参考文献
1) Go AS, et al : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 : 1296-1305, 2004.
PubMed
2) Anavekar NS, et al : Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 : 1285-1295, 2004.
PubMed
3) Reddan D N, et al : Chronic kidney disease, mortality, and treatment strategies among patients with clinically signincant coronary artery disease. J Am Soc Nephrol 14 : 2373-2380, 2003.
PubMed
4) Joki N, et al : Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 12 : 718-723, 1997.
PubMed
5) Yasuda K, et al : Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol 17 : 2322-2332, 2006.
PubMed
6) Gowdak LH, et al : Screening for significant coronary artery disease in high-risk renal transplant candidates. Coron Artery Dis 18 : 553-558, 2007.
PubMed
7) Soubassi LE et al : Incidence and risk factors of coronary artery disease in patients on chronic hemodialysis. Int J Artif Organs 30 : 253-257, 2007.
 
8) Hase H, et al : Independent risk factors for progression of coronary atherosclerosis in hemodialysis patients. Ther Apher Dial 10 : 321-327, 2006.
PubMed
9) Hase H, et al : Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int 70 : 1142-1148, 2006.
 
10) Ohtake T, et al : High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy : an angiographic examination. J Am Soc Nephrol 16 : 1141-1148, 2005.
PubMed
11) Cho I, et al : Coronary atherosclerosis detected by coronary CT angiography in asymptomatic subjects with early chronic kidney disease. Atherosclerosis 208 : 406-411, 2010.
PubMed
12) Miyagi M, et al : Impact of renal function on coronary plaque composition. Nephrol Dial Transplant 25 : 175-181, 2010.
PubMed
13) Rigatto C, et al : Atheroma progression in chronic kidney disease. Clin J Am Soc Nephrol 4 : 291-298, 2009.
PubMed
14) Nakano T, et al : Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders : the Hisayama study. Am J Kidney Dis 55 : 21-30, 2010.
PubMed
15) Hong YJ, et al : Effect of renal function on ultrasonic coronary plaque characteristics in patients with acute myocardial infarction. Am J Cardiol 105 : 936-942, 2010.
PubMed
16) Kono K et al : Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. Kidney Int 82 : 344-351, 2012.
PubMed
17) Niizuma S, et al : Kidney function and histological damage in autopsy subjects with myocardial infarction. Ren Fail 33 : 847-852, 2011.
PubMed
18) Temmar M, et al : Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 28 : 163-169, 2010.
PubMed
19) Caliskan Y, et al : Coronary artery calcification and coronary flow velocity in haemodialysis patients. Nephrol Dial Transplant 25 : 2685-2690, 2010.
PubMed
20) Rostand SG, et al : Dialysis-associated ischemic heart disease : insights from coronary angiography. Kidney Int 25 : 653-659, 1984.
PubMed
21) Herzog CA et al : Clinical characteristics of dialysis patients with acute myocardial infarction in the United States : a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 116 : 1465-1472, 2007.
 
22) Bae EH, et al : GFR and cardiovascular outcomes after acute myocardial infarction : results from the Korea Acute Myocardial lnfarction Registry. Am J Kidney Dis 59 : 795-802, 2012.
 
P.483 掲載の参考文献
1) Festa JR et al : Association of low ejection fraction with impaired verbal memory in older patients with heart failure. Arch Neurol 68 : 1021-1026, 2011.
PubMed
2) Zuccalb G, et al : Correlates of cognitive impairment among patients with heart failure : results of a multicenter survey. Am J Med 118 : 496-502, 2005.
 
3) Almeida OP, et al : Congestive heart failure and cognitive functioning amongst older adults. Arq Neuropsiquiatr 59 : 324-329, 2001.
PubMed
4) Acanfora D, et al : The brain in congestive heart failure. Arch Gerontol Geriatr 23 : 247-256, 1996.
PubMed
5) Cacciatore E et al : Congestive heart failure and cognitive impairment in an older population. Osservatorio Geriatrico Campano Study Group. J Am Geriatr Soc 46 : 1343-1348, 1998.
 
6) Sauve MJ, et al : Cognitive impairments in chronic heart failure : a case controlled study. J Card Fail 15 : 1-10, 2009.
PubMed
7) Trojano L, et al : Cognitive impairment : a key feature of congestive heart failure in the elderly. J Neurol 250 : 1456-1463, 2003.
PubMed
8) Almeida OP, et al : Two-year course of cognitive function and mood in adults with congestive heart failure and coronary artery disease : the Heart-Mind Study. Int Psychogeriatr 24 : 38-47, 2012.
PubMed
9) Jefferson AL, et al : Relation of left ventricular ejection fraction to cognitive aging (from the Framingham Heart Study). Am J Cardiol 108 : 1346-1351, 2011.
PubMed
10) Qiu C, et al : Decline in blood pressure over time and risk of dementia : alongitudinal study from the Kungsholmen project. Stroke 35 : 1810-1815, 2004.
 
11) Putzke JD, et al : Neuropsychological functioning among heart transplant candidates : a case control study. J Clin Exp Neuropsychol 22 : 95-103, 2000.
PubMed
12) Ekman I, et al : The clinical implications of cognitive impairment in elderly patients with chronic heart failure. J Cardiovasc Nurs 16 : 47-55, 2001.
PubMed
13) Cermakova P, et al : Heart failure and dementia : survival in relation to types of heart failure and different dementia disorders. Eur J Heart Fail 17 : 612-619, 2015.
PubMed
14) Vogels RL, et al : Brain magnetic resonance imaging abnormalities in patients with heart failure. Eur J Heart Fail 9 : 1003-1009, 2007.
PubMed
15) Jefferson AL, et al : Cardiac index is associated with brain aging : the Framingham Heart Study. Circulation 122 : 690-697, 2010.
PubMed
16) Shimizu A et al : Left ventricular diastolic dysfunction is directly associated with cerebral white matter lesions in elderly patients. Geriatr Gerontol Int 15 Suppl 1 : 81-82, 2015.
 
17) Tranmer BI, et al : Loss of cerebral regulation during cardiac output variations in focal cerebral ischemia. J Neurosurg 77 : 253-259, 1992.
PubMed
18) Lassen NA : Cerebral blood flow and oxygen consumption in man. Physiol Rev 39 : 183-238, 1959.
PubMed
19) Massaro AR, et al : Transcranial Doppler assessment of cerebral blood flow : effect of cardiac transplantation. Neurology 66 : 124-126, 2006.
PubMed
20) Gruhn N, et al : Cerebral blood flow in patients with chronic heart failure befbre and after heart transplantation. Stroke 32 : 2530-2533, 2001.
PubMed
21) Jefferson N : Cardiac output as a potential risk factor for abnormal brain aging. J Alzheimers Dis 20 : 813-821, 2010,
 
22) Gibbs CR et al : Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm : effects of angiotensin-converting enzyme inhibitor and betablocker therapy. Circulation 103 : 1746-1751, 2001.
PubMed
23) Kovacic JC, et al : Cellular senescence, vascular disease, and aging : part 2 of a 2-part review : clinical vascular disease in the elderly. Circulation 123 : 1900-1910, 2011.
PubMed
24) Pluta R : The role of apolipoprotein E in the deposition of beta-amyloid peptide during ischemiareperfusion brain injury. A model of early Alzheimer's disease. Ann N Y Acad Sci 903 : 324-334, 2000.
 
25) Aliev G, et al : Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 4 : 649-663, 2004.
PubMed
26) Bell RD, et al : Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118 : 103-113, 2009.
 
P.488 掲載の参考文献
1) Owan ET et al : Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47 : 320-332, 2005.
 
2) Young JB : The prognosis of heart failure. In : Heart Failure. A companion to Braunwald's Heart Disease. (ed by D. L Mann), ed 2 pp501-510, WB Saunders, Philadelphia, 2011
 
3) Calle EE, et al : Body-mass index and mortality in a prospective cohort of U. S. adults. N Engl J Med 341 : 1097-1105, 1999.
 
4) Horwich TB, et al : The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 : 789-795, 2001.
PubMed
5) Ghali JK et al : Survival of heart failure patients with preserved versus impaired systolic function : the prognostic implication of blood pressure. Am Heart J 123 : 993-997, 1992.
PubMed
6) Puhgnano G, et al : Clmical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units : data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 143 : 45-55, 2002.
 
7) Levy WC, et al : The Seattle Heart Failure Model : prediction of survival in heart failure. Circuladon 113 : 1424-1433, 2006.
PubMed
8) Bhatia RS, et al : Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 : 260-269, 2006.
 
9) Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) : The survival of padents with heart failure with preserved or reduced left ventricular ejection fraction : an individual patient data meta-analysis. Eur Heart J 33 : 1750-1757, 2012.
 
10) Chan MM, et al : How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 15 : 604-613, 2013.
PubMed
11) Henkel DM, et al : Death in heart failure : a community perspective. Circ Heart Fail 1 : 91-97, 2008.
PubMed
12) Felker GM, et al : A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 39 : 210-218, 2002.
PubMed
P.494 掲載の参考文献
1) 「輸血療法の実施に関する指針」 (改訂版) および「血液製剤の使用指針」 (改訂版) http://www.mhlw.go.jp/new-info/kobetu/iyaku/kenketsugo/tekisei120319.html厚生労働省
 
2) Carson JL, et al : Red blood cell transfusion : a clinical practice guideline from the AABB*. Ann Intern Med 157 : 49-58, 2012.
PubMed
3) 草間芳樹, ほか : 併存疾患の薬物治療-貧血と狭心症. 治療 75 : 2, 1993.
 
4) 川田紀彦, ほか : 重症貧血に伴い不安定狭心症を呈した1例. Circ J 72 : Suppl III, 2008.
 
5) 松原欣也, ほか : 貧血の増悪により繰りかえし誘発される不安定狭心症の1例. Jpn Circ J 53, Suppl I, 1989.
 
6) Hamaguchi S, et al : Anemia is an independent predictor of long-term adverse outcomes in patients hosphalized with heart failure in Japan. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73 : 1901-1908, 2009.
PubMed
7) Silverberg DS, et al : Intravenous iron in heart failure : beyond targeting anemia. Curr Heart Fail Rep 8 : 14-21, 2011.
PubMed
8) Anker SD, et al : Ferric carboxy maltose in patients with heart failure and iron deficiency. N Engl J Med 361 : 2436-48, 2009.
 
9) Kansagara D, et al : Treatment of anemia in patients with heart disease : a systematic review. Ann Intern Med 159 : 746-757, 2013.
PubMed
10) Andrzejewski C, et al : How we view and approach transfusion-associated circulatory overload : pathogenesis, diagnosis, management, mitigation, and prevention. Transfusion 53 : 3037-3047, 2013.
PubMed
11) Robillard P, et al : Transfusion-Associated Circulatory Overload (TACO) : The new leading cause of transfusion-associated fatalities reported to the Qu6bec Hemovigilance System. Available from : TACO-data-200 (L2008-ISBT-2010.
 

XVI 川崎病の臨床

P.502 掲載の参考文献
1) 川崎富作 : 指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群 : 自験例50例の臨床的観察. アレルギー16 : 178-222, 1967.
 
2) 小児MCLS研究班 (班長 : 神前章雄). 小児MCLS全国調査成績, 昭和45年度予備調査成績と昭和46年度個人調査成績の概要. 1971.
 
3) 重松逸造, 柳川洋. いわゆる川崎病について. 日本公衛誌 22 (6) : 306-312, 1975.
 
4) 柳川洋 : 川崎病の実態. 公衆衛生情報 5 (12) : 22-29, 1975.
 
5) 柳川洋 : 川崎病の疫学. 日本臨牀 34 (2) : 275-283, 1976.
Medical*Online
6) 川崎病研究班. 最近 (1977-78年) におけるMCLS (川崎病) の実態, -第5回全国調査結果の速報-. 小児科 20 (7) : 755-757, 1979.
 
7) 川崎病研究班. MCLS (川崎病の多発) -第6回全国調査成績の速報-. 小児科 22 (1) : 53-58, 1981.
 
8) 川崎病研究班. 最近 (1981年1月-82年6月) におけるMCLS (川崎病) の実態, -第7回全国調査成績の速報-. 小児科 24 (1) : 53-58, 1983.
 
9) 厚生省川崎病研究班. 第8回川崎病全国調査成績. 小児科 26 (9) : 1049-1053, 1985.
 
10) 厚生省川崎病研究班. 第9回川崎病全国調査成績. 小児科 28 (9) : 1059-1066, 1987.
 
11) 厚生省川崎病研究班. 第10回川崎病全国調査成績. 小児科 31 (5) : 569-576, 1990.
 
12) 厚生省川崎病研究班. 第11回川崎病全国調査成績. 小児科 33 (3) : 309-316, 1992.
 
13) 厚生省川崎病研究班. 第12回川崎病全国調査成績. 小児科 35 (1) : 61-73, 1994.
 
14) 厚生省川崎病研究班. 第13回川崎病全国調査成績. 小児科 37 (4) : 363-383, 1996.
 
15) 厚生省川崎病研究班. 第14回川崎病全国調査成績. 小児科診療 61 (3) : 406-420, 1998.
Medical*Online
16) 厚生省川崎病研究班. 第15回川崎病全国調査成績. 小児科診療 63 (1) : 121-132, 2000.
 
17) 厚生省川崎病研究班. 第16回川崎病全国調査成績. 小児科診療 65 (2) : 332-342, 2002.
 
18) 厚生労働省川崎病研究班. 第17回川崎病全国調査成績. 小児科診療 67 (2) : 313-323, 2004.
 
19) 厚生労働省川崎病研究班. 第18回川崎病全国調査成績. 小児科診療 69 (2) : 281-292, 2006.
 
20) 厚生労働省川崎病研究班. 第19回川崎病全国調査成績. 小児科診療 71 (2) : 349-360, 2008.
 
21) 川崎病全国調査担当グループ (特定非営利活動法人川崎病研究センター). 第20回川崎病全国調査成績. 小児科診療 73 (1) : 143-156, 2010.
 
22) 川崎病全国調査担当グループ (特定非営利活動法人川崎病研究センター). 第21回川崎病全国調査成績. 小児科診療 75 (3) : 507-523, 2012.
Medical*Online
23) 川崎病全国調査担当グループ (特定非営利活動法人川崎病研究センター). 第22回川崎病全国調査成績. 小児科診療 77 (2) : 271-290, 2014.
Medical*Online
24) 川崎病全国調査担当グループ (特定非営利活動法人川崎病研究センター). 第23回川崎病全国調査成績. 小児科診療 79 (2) : 273-292, 2016.
Medical*Online
25) 日本川崎病学会用語委員会 : 川崎病の用語に関する規定. [http://www.jskd.jp/info/pdf/yougo201007.pdf]
 
P.507 掲載の参考文献
1) Shulman ST et al : Kawasaki disease : insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol 11 : 475-482, 2015.
PubMed
2) 森雅亮 : 川崎病の病態と治療 (小児リウマチ性疾患 : 病態解明と治療の新展開). 炎症と免疫 22 : 105-109, 2014.
 
3) 屋代真弓, ほか : 第23回川崎病全国調査成績. 小児科診療 79 : 273-292, 2016.
Medical*Online
4) http://www.jichi.ac.jp/dph/kawasakibyou/20150924/mcls23report1013.pdf
 
5) Awaya A et al : A combination of cross correlation and trend analyses reveals that Kawasaki disease is a pollen-induced delayed-type hyper-sensitivity disease. Int J Environ Res Public Health 11 : 2628-2641, 2014.
PubMed
6) Wu MH, et al : State-of-th-art basic and clinical science of Kawasaki disease : The 9th International Kawasaki Disease Symposium 10-12 April 2008, Taipei, Taiwan. Pediatr Health 2 : 405-409, 2008.
 
7) Singh S, et al : Is Kawasaki disease incidence rising in Chandigarh, North India? Arch Dis Child 96 : 137-140, 2011.
PubMed
8) 上原里程 : 疫学から (川崎病の本態にせまる : 古くて新しい研究から). 小児科診療 74 : 1097-1102, 2011.
 
9) 川崎富作 : 指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群 : 自験例50例の臨床的観察. アレルギー 16 : 178-222, 1967. (この論文はhttp://www.jskd.jp/info/pdf/kawasaki.pdfで, 英文対訳付きで閲覧可能)
 
10) Uehara R, et al : Parents with a history of Kawasaki disease whose child also had the same disease. Pediatr Int 53 : 511-514, 2011.
PubMed
11) Fujita Y, et al : Kawasaki disease in families. Pediatrics 84 : 666-669, 1989.
PubMed
P.512 掲載の参考文献
1) Fuse S, et al : Standard method for ultrasound imaging of coronary artery in children. Pediatr Int 52 : 876-882, 2010.
PubMed
2) 広瀬修, ほか : 心断層エコー図による川崎病の冠動脈像 : 冠動脈瘤の発見, 急性期の所見および冠動脈瘤の経時的変化. J Cardiogr II 81) : 89-104, 1981.
 
3) 日本川崎病研究センター : 第22回川崎病全国調査成績, 2013年9月.
 
4) 北爪勉, ほか : MRIによる川崎病の冠動脈壁肥厚の検討. 日小循誌 27 : 35-37, 2011.
Medical*Online
5) Suzuki A, et al : Functional behavior and morphology of the coronary artery wall in patients with Kawasaki disease assessed by intravascular ultrasound. J Am Coll Cardiol 27 : 291-296, 1996.
 
6) 鈴木淳子 : 川崎病冠動脈病変の心エコー図診断の標準化. 小児の超音波診断. 小児科Mook増刊 1, p160-170, 金原出版, 1986.
 
7) Suzuki A et al : Fate of coronary arterial aneurysms in Kawasaki disease. Am J Cardiol 74 : 822-824, 1994.
PubMed
8) 鈴木淳子, ほか : 川崎病による冠動脈狭窄性病変の出現と進展. 日小循誌 7 : 653-658, 1992.
Medical*Online
9) 鈴木淳子, ほか : MRIによる川崎病冠動脈障害の経過観察-特に瘤内血栓の経過-. Prog Med 34 : 1250-1256, 2014.
Medical*Online
10) Suzuki A, et al : Magnetic resonance coronary angiography to evaluate coronary arterial lesions in patients with Kawasaki disease. Cardiol Young 16 : 563-571, 2006.
PubMed
11) Takemura A, et al : Utility of coronary MR angiography in children with Kawasaki disease. AIR Am J Roentgenol 188 : W534-W539, 2007.
 
12) 鈴木淳子 : MRIによる川崎病冠動脈病変と心筋障害の評価. 循環器科 64 : 103-110, 2008.
 
13) 丸宮怜, ほか : マルチディテクターCTを用いた川崎病冠動脈病変の検討. 近畿大医誌 36 : 91-100, 2011.
 
14) 大山伸雄ほか : 128列Dual-Source CTを用いた鎮静・自発呼吸での川崎病性冠動脈瘤既往例の超低被ばく冠動脈CT. 心臓 44 : 1449-1450, 2012.
 
15) Tanaka R, et al : Improved evaluation of calcified segments on coronary CT angiography ; A feasibility study of coronary calcium subtraction. Int J Cardiovasc Imaging 29 (Suppl 2) : 75-81, 2013.
 
P.516 掲載の参考文献
1) Newburger JW, et al : A single intravenous infusion of gamma globunn as compared with fbur infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324 : 1633-1639, 1991.
 
2) Kobayashi T et al : Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded-endpoints trial. Lancet 379 : 1613-1620, 2012.
PubMed
3) Tremoulet AH, et al : Infliximab for intensification of primary therapy for Kawasaki disease : a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383 : 1731-1738, 2014.
PubMed
4) Matsubara T et al : Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 56 : 29-36, 1990.
PubMed
5) Hamada H, et al : Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulinresistant Kawasaki disease. Cytokine 60 : 681-685, 2012.
PubMed
6) Kobayashi T et al : Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113 : 2606-2612, 2006.
PubMed
7) Egami K et al : Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149 : 237-240, 2006.
PubMed
8) Sano T, et al : Prediction of non-responsiveness to standard highdose garmna-globulin trerapy in patients with acute Kawasald disease before starting initial treatment. Eur J Pediatr 166 : 131-137, 2007.
 
9) Sleeper LA, et al : Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 158 : 831-835 e833, 2011.
 
10) Mantovani A et al : The long pentraxin PTX3 : a paradigm for humoral pattern recognition molecules. Ann N Y Acad Sci 1285 : 1-14, 2013.
 
11) Kitoh T, et al : Pentraxin 3 in Coronary Artery Lesions in Kawasaki Disease. Circulation 131 : A88, 2015.
 
12) Katsube Y, et al : PTX3, a new biomarker for vasculitis, predicts intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. J Am Coll Cardiol 57 : E2038-E2038, 2011.
 
13) Masuzawa Y, et al : Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease. Ther Apher Dial 19 : 171-177, 2015.
 
14) Yoshimura K, et al : N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease. J Pediatr 162 : 1205-1209, 2013.
PubMed
15) Ye Q, et al : A Comprehensive Assessment of the Value of Laboratory Indices in Diagnosing Kawasaki Disease. Arthritis & Rheumatology 67 : 1943-1950, 2015.
 
P.520 掲載の参考文献
1) 三浦大 : 典型例をアスピリンで治療する. 小児科診療 78 : 341-346, 2015.
Medical*Online
2) Kato H, et al : Kawasaki disease : effect of treatment on coronary artery involvement. Pediatrics 63 : 175-179, 1979.
PubMed
3) 草川三治, ほか : 川崎病の急性期治療研究 (第3報) -Aspirin, Flurbiprofen, Prednisolone+Dipyridamoleの3治療群によるprospective study. 日小児会誌 90 : 1844-1849, 1986.
 
4) Baumer JH, et al : Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 18 : CD004175, 2006.
 
5) 佐地勉, ほか : 川崎病急性期治療のガイドライン (平成24年改訂版). 日小循誌 28 (Supplement 3) s1-s28, 2012.
 
6) Newburger JW, et al : Diagnosis, treatment, and long-term management of Kawasaki disease : a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110 : 2747-2771, 2004.
 
7) Eleftheriou D, et al : Management of Kawasaki disease. Arch Dis Child 99 : 74-83, 2014.
PubMed
8) 小川俊一, ほか : 川崎病心臓血管後遺症の診断と治療に関するガイドライン (2013年改訂版). http://www.j.circ.or.jp/guideline/pdf/JCS2013_ogawas_h.pdf.
 
9) Durongpisitkul K et al : The prevention of coronary artery aneurysm in Kawasaki disease : ametaanalysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96 : 1057-1061, 1995.
 
10) Terai M, et al : Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 131 : 888-893, 1997.
 
11) Nakada T : Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the acute phase of Kawasaki disease. Pediatr Cardiol 36 : 335-339, 2015.
PubMed
12) Kuo HC, et al : High-Dose Aspirin Is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease. PLoS ONE 10 : e0144603, 2015.
PubMed
13) 堀正二, ほか : 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_hori_h.pdf.
 
14) 田中智之 : 川崎病における肝障害-病理. 小児内科 16 : 2393-2397, 1984.
 
15) 浜田洋通 : アスピリン. 日本臨牀 72 : 1612-1616, 2014
Medical*Online
16) Takeuchi M, et al : Maculopapular rash in the convalescent phase of Kawasaki disease : case series and literature review. Eur J Pediatr 172 : 405-407, 2013.
PubMed
P.525 掲載の参考文献
1) Burns JC, et al : Kawasaki syndrome. Lancet 364 : 533-544, 2004.
PubMed
2) 川崎富作 : 指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴腺症候群. アレルギー 16 : 178-222, 1967.
Medical*Online
3) Kato H, et al : Kawasaki disease : effect of treatment on coronary artery involvement. Pediatrics 63 : 175-179, 1979.
PubMed
4) Furusho K, et al : High-dose intravenous gammaglobulin for Kawasaki disease. Lancet ii : 1055-1058, 1984.
 
5) Burns JC, et al : US/Canadian Kawasaki Syndrome Study Group. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 17 : 1144-1148, 1998.
 
6) 佐地勉, ほか : 川崎病急性期治療のガイドライン. 日本小児循環器学会雑誌 20 (1) : 54-62, 2004.
Medical*Online
7) Egami K, et al : Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149 : 237-240, 2006.
PubMed
8) Kobayashi T, et al : Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 113 : 2606-2612, 2006.
PubMed
9) Sano T, et al : Prediction of non-responsiveness to standard highdose gamma-globulm therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 166 : 131-137, 2007.
PubMed
10) Ogata S, et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease : a randomized trial. Pediatrics 129 : e17-23, 2012,
PubMed
11) Kobayashi T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded-endpoints trial. Lancet 379 : 1613-1620, 2012.
PubMed
12) 佐地勉, ほか : 日本小児循環器学会研究委員会研究課題「川崎病急性期治療のガイドライン」 (平成24年改訂版) 日本小児循環器学会雑誌 28 (suppl-3) : 4997-5028, 2012.
 
13) Furukawa T, et al : Effects of steroid pulse therapy on immunoglobulm-resistant Kawasaki disease. Arch Dis Child 93 : 142-146, 2008.
 
14) Miura M, et al : Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 90 : 1096-1097, 2005.
PubMed
15) Miura M, et al : Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy. Paediatr Child Health 16 : 479-484, 2011.
PubMed
P.531 掲載の参考文献
1) 佐地勉, ほか : 川崎病急性期治療のガイドライン (平成24年改訂版). 日本小児循環器学会雑誌 28 supple 3 : s1-s28, 2012.
 
2) Mueller F, et al : Long-term follow-up of acute changes in coronary artery diameter caused by Kawasaki disease : risk factors for development of stenotic lesions. Clin Res Cardiol 98 : 501-507, 2009.
PubMed
3) Tsuda E, et al : Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter durig Kawasaki disease. Pediatr Cardiol 26 : 73-79, 2005.
 
4) Nakada T : Prevention of large coronary artery lesions caused by Kawasaki disease. Med Res Arch 2015. DOI : http://dx.doi.org/10.18103/mra.v0i3.138
 
5) Kobayashi T, et al : Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded-endpoints trial. Lancet 379 : 1613-1620, 2012.
PubMed
6) Tremoulet AH, et al : Infliximab for intensification of primary therapy for Kawasaki disease : a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 383 : 1731-1738, 2014.
PubMed
7) Hsieh KS, et al : Treatment of acute Kawasaki disease : aspirin's role in the febrile stage revisited. Pediatrics 114 : e689-693, 2004.
PubMed
8) Lee G, et al : Is high-dose aspirin necessary in the acute phase of kawasaki disease? Korean Circ J 43 : 182-186, 2013.
PubMed
9) Nakada T : Background factors associated with the complications of coronary artery lesions caused by Kawasaki disease. Clin Med Res 4 : 127-131, 2015.
 
10) Nakada T : Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the acute phase of Kawasaki disease. Pediatr Cardiol 36 : 335-339, 2015.
PubMed
11) 清沢伸幸, ほか : 京都第二赤十字病院小児科における川崎病急性期治療結果について. 京都第二赤十字病院医学雑誌 35 : 2-11, 2014.
 
12) 高原賢守, ほか : 重症川崎病に対する血漿交換療法施行の現状-血漿交換療法施行60例の検討より-. Progress in Medicine 34 : 1282-1287, 2014.
Medical*Online
13) 中田利正 : 免疫グロブリン療法不応川崎病に対する追加治療時期に関する検討. 小児科臨床 67 : 122-127, 2014.
Medical*Online
14) 中田利正 : 川崎病急性期追加治療適応診断におけるC-reactive proteinの有用性. 青森県立中央病院医誌 60 : 1-6, 2015.
 
15) 中田利正 : 治療開始前に冠動脈病変を合併していた川崎病の検討. 小児科臨床 68 : 1410-1414, 2015.
Medical*Online
P.536 掲載の参考文献
1) 森雅亮 : サイトカイン阻止による治療効果からみた炎症の考え方 (1) -川崎病-. 臨床とウイルス 42 : 104-111, 2014.
Medical*Online
2) 阿部淳 : サイトカインと病態. 小児内科 46 : 722-726, 2014.
Medical*Online
3) 阿部淳 : 川崎病とサイトカイン. 日本臨牀 72 : 1548-1553, 2014.
Medical*Online
4) Mori M, et al : Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 14 : 43-47, 2004.
PubMed
5) Hokosaki T, et al : Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int 54 : 99-103, 2012.
PubMed
6) Sonoda K et al : Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr 164 : 1128-1132. e1, 2014.
 
P.540 掲載の参考文献
1) Ogawa S, et al : Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J 78 : 2521-2562, 2014.
 
2) 津田悦子, ほか : 小児の集中治療 急性心筋梗塞. 東京医学社 139-143, 2000.
 
3) Kawai H, et al : Two cases with past Kawasaki disease developing acute myocardial infarction in their thirties, despite being regarded as at low risk for coronary events. Heart Vessels 30 : 549-553, 2015.
PubMed
4) Tsuda E, et al : Acute coronary syndrome in adult patients with coronary artery lesions caused by Kawasaki disease : review of case reports. Cardiol Young 21 : 74-82, 2011.
PubMed
5) Gordon J, et al : The spectrum of cardiovascular lesions requiring intervention in adults after Kawasaki disease. JACC Cardiovasc Interv 9 : 687-696, 2016.
PubMed
6) Kitamura S. The role of coronary bypass operation on children with Kawasaki disease. Coron Artery Dis 13 : 437-447, 2002.
PubMed
7) Kitamura S, et al : Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawasaki disease. Circulation 120 : 60-68, 2009.
PubMed
8) 津田悦子. 成人期における川崎病冠動脈障害に対する冠動脈バイパス手術. 心臓 45 : 967-971, 2013.
Medical*Online
9) Tsuda E : Coronary artery bypass grafting for coronary artery stenosis caused by Kawasaki disease. Expert Rev Cardiovasc Ther 7 : 533-539, 2009.
PubMed
10) 川崎智広, 三角和雄. 川崎病後遺症への最新カテーテル治療. 心臓 45 : 962-966, 2013.
 
11) Tsuda E, et al : Strategy for localized stenosis caused by Kawasaki disease : midterm results of percutaneous transluminal coronary balloon angioplasty in two infants. Pediatr Cardiol 27 : 272-275, 2006.
PubMed
12) Tsuda E, et al : Percutaneous transluminal coronary rotational atherectomy for localized stenosis caused by Kawasaki disease. Pediatr Cardiol 27 : 447-453, 2006.
PubMed
13) 横井宏佳. 川崎病冠動脈後遺症に対する冠動脈インターベンション. 心臓 45 : 958-961, 2013.
Medical*Online
14) Akagi T : Interventions in Kawasaki disease. Pediatr Cardiol 26 : 206-212, 2005.
PubMed
15) Sawai T, et al : New coronary aneurysm formation and malapposition after zotarolimus-eluting stent implantation in Kawasaki disease. J Cardiol Cases 8 : 118-120, 2013.
PubMed
P.545 掲載の参考文献
1) 日本循環器学会. 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 川崎病心臓血管後遺症の診断と治療に関するガイドライン (2013年改変版). http://www.kawasaki-m.ac.jp/hospital/dept/document/016/guidelines_kawasaki-2.pdf
 
2) Kato H, et al : Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation 94 : 1379-1385, 1996.
PubMed
3) Suda K, et al : Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms : a single-institUtion experience. Circulation 123 : 1836-1842, 2011.
PubMed
4) Manlhiot C, et al : Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol 31 : 242-249, 2010.
PubMed
5) Wilson W, et al : Prevention of infective endocarditis : gtiidelines from the American Heart Association : a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116 : 1736-1754, 2007.
 
6) Su D, et al : Safety and efficacy of warfarin plus aspirin combination therapy for giant coronary artery aneurysm secondary to Kawasaki disease : a meta-analysis. Cardiology 129 : 55-64, 2014.
PubMed
7) Harada M, et al : National Japanese survey of thrombolytic therapy selection for coronary aneurysm : intracoronary thrombolysis or intravenous coronary thrombolysis in patients with Kawasaki disease. Pediatr Int 55 : 690-695, 2013.
PubMed
8) Cheung YE et al : Novel and traditional cardiovascular risk factors in children after Kawasaki disease : implications for premature atherosclerosis. J Am Coll Cardiol 43 : 120-124, 2004.
 
9) Mitani Y, et al : Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease : association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 111 : 38-43, 2005.
PubMed
10) Suda K et al : Persistent coronary arterial inflammation in a patient long after the onset of Kawasaki disease. Int J Cardiol 154 : 193-194, 2012.
 
11) Huang SM, et al : Effects of statin therapy in children complicated With coronary arterial abnormality late after Kawasaki disease : a pilot study. Circ J 72 : 1583-1587, 2008.
PubMed
12) Hamaoka A et al : Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease. J Cardiol 56 : 245-253, 2010.
PubMed
13) Suda K, et al : Statin reduces persistent coronary arterial inflammation evaluated by serial 18fluorodeoxyglucose positron emission tomography imaging long after Kawasaki disease. Int J Cardiol 179 : 61-62, 2015.
PubMed
14) Hauser M, et al : Myocardial blood flow and coronary flow reserve in children with "normal" epicardial coronary arteries after the onset of Kawasaki disease assessed by positron emission tomography. Pediatr Cardiol 25 : 108-112, 2004.
PubMed
15) Tsuda E, et al : Two young adults who had acute coronary syndrome after regression of coronary aneurysms caused by Kawasaki disease in infancy. Pediatr Cardiol 27 : 372-375, 2006.
PubMed
P.549 掲載の参考文献
1) 中村好一, 屋代真弓 : 疫学からみた川崎病死亡例. 循環器内科 69 (4) : 412-420, 2011.
 
2) http://www.jichi.ac.jp/dph/kawasaki.html
 
3) 日本川崎病研究会運営委員会 : 川崎病の管理基準 (2002年改訂). 日児誌 107 : 166-167, 2003.
 
4) http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawas_h.pdf
 
5) Newburger JW, et al : Diagnosis, treatment, and long-teml management of Kawasaki disease : a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 110 : 2747-2771, 2004.
 
6) Kavey RE, et al : Cardiovascular risk reduction in high-risk pediatric patients : ascientific statement from the American Heart Association Expert Panel on Population and Prevention Science ; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease ; and the lnterdisciplinary Working Group on Quality of Care and Outcomes Research : endorsed by the American Academy of Pediatrics. Circulation 114 : 2710-2738, 2006.
 
7) 三谷義英 : 川崎病と成人急性冠症候群. 循環器内科 69 : 366-370, 2011.
 
8) Dhillon R, et al : Endothelial dysfunction late after Kawasaki disease. Circulation 94 : 2103-2106, 1996.
PubMed
9) Yamakawa R, et al : Coronary endothelial dysfunction after Kawasaki disease : evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol 31 : 1074-1080, 1998.
PubMed
10) Mitani Y, et al : Impaired endothelial function in epicardial coronary arteries after Kawasaki disease. Circulation 96 : 454-461, 1997.
PubMed
11) Niboshi A, et al : Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 167 : 189-196, 2008.
PubMed
12) Hamaoka A, et al : Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease. J Cardiol 56 : 245-253, 2010.
PubMed
13) Mitani Y, et al : Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease : association between inflammation and late coronary sequelae in Kawasaki disease. Circulation l l 1 : 38-43, 2005.
 
14) Sugimura T, et al : Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 89 : 258-265, 1994.
PubMed
15) Sugimura T, et al : Interventional treatment for children with severe coronary artery stenosis with calcification after long-term Kawasaki disease. Circulation 96 : 3928-3933, 1997.
PubMed
16) Mitani Y, et al : In vivo plaque composition and morphology in coronary artery lesions in adolescents and young adults long after Kawasaki disease : avirtual histology-intravascular ultrasound study. Circulation 119 : 2829-2836, 2009.
 
17) Tsuda E, et al : Coronary artery dilatation exceeding 4.0 mm during acute Kawasaki disease predicts a high probability of subsequent late intima-medial thickening. Pediatr Cardiol 23 : 9-14, 2002.
 
18) Dionne A, et al : Coronary Wall Structural Changes in Patients With Kawasaki Disease : New Insights From Optical Coherence Tomography (OCT). J Am Heart Assoc 4 : pii : e001939, 2015.
 

XVII 特論

P.555 掲載の参考文献
1) 相澤義房, ほか : 循環器病の診断と治療に関するガイドライン (2003-2004年度合同研究班報告). 心臓突然死の予知と予防法のガイドライン. Circ J 69 (Suppl. IV) : 1209-12521, 2005.
 
2) O'Doherty M, et al : Five hundred patients with myocardial infarction monitored within one hour of symptoms. Br Med J 286 : 1405-1408, 1983.
 
3) Mehta RH, et al : Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA 301 : 1779-1789, 2009.
 
4) Gheeraert PJ, et al : Risk factors for primary ventricular fibrillation during acute myocardial infarction : a systematic review and meta-analysis. Eur Heart J 27 : 2499-2510, 2006.
PubMed
5) Naruse Y, et al : Early repolarization is an independent predictor of occurrences of ventricular fibrillation in the very early phase of acute myocardial infarction. Circ Arrhythm Electrophysiol 5 : 506-513, 2012.
PubMed
6) Aizawa Y, et al : Characteristics of electrocardiographic repolarization in acute myocardial infarction complicated by ventricular fibrillation. J Electrocardiol 45 : 252-259, 2012.
PubMed
7) 循環器病の診断と治療に関するガイドライン. 不整脈薬物治療に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_kodama_h.pdf (2010年6月閲覧).
 
8) Mont L, et al : Predisposing factors and prognostic value of sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction. J Am Coll Cardiol 28 : 1670-1676, 1996.
PubMed
9) JCS Joint Working Group : Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JCS 2011). Circ J 77 : 249-274, 2013.
 
10) Connolly SJ, et al : Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21 : 2071-2078, 2000.
PubMed
11) Connolly SJ, et al : Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators : the OPTIC Study : a randomized trial. JAMA 295 : 165-171, 2006.
PubMed
12) Goldenberg I, et al : Long-term benefit of primary prevention with an implantable cardioverterdefibrillator : an extended&year fOllow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 122 : 1265-1271, 2010.
PubMed
13) Shiga T, et al : Sudden cardiac death and left ventricular ejection fraction during long-term follow-up after acute myocardial infarction in the primary percutaneous coronary intervention era : results from the HIJAMI-II registry. Heart 95 : 216-220, 2009.
PubMed
14) Bristow MR, et al : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 : 2140-2150, 2004.
 
15) Noda T, et al : Malignant type of electrical storm in patients with ah implantable Cardiac Shock Device : Results From the Nippon Storm Study AHA Scientific Session, Orlando, Florida, 2015.
 
P.561 掲載の参考文献
1) 神出計, 樂木宏実 : Jカーブ理論の再燃. 医学のあゆみ 241 : 13, 2013.
 
2) 日本高血圧学会 : 高血圧治療ガイドライン 2014 [JSH2014], 2014.
 
3) Fukuhara M, et al : Impact of lower range of prehypertension on cardiovascular events in a general population : the Hisayama Study. J Hypertens 30 : 893-900, 2012.
 
4) Staessen JA et al : Risks of untreated and treated isolated systolic hypertension in the elderly : metaanalysis of outcome trials. Lancet 355 : 865-872, 2000.
PubMed
5) Noda H, et al : The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke : the Japan public health center-based study. Hypertens Res 32 : 289-298, 2009.
PubMed
6) 今野弘規, 磯博康 : 我が国の高血圧の疫学. 最新臨床高血圧学 72 : 14-19, 2014.
 
7) Kokubo Y, et al : Impact of high-normal blood pressure on the risk of cardiovascular disease in a Japanese urban cohort : the Suita study. Hypertension 52 : 652-659, 2008.
 
8) Messerli FH, et al : Dogma disputed : Can aggressively hypertensive patients with coronary artery lowering blood pressure in disease be dangerous? Ann Intern Med 144 : 884-893, 2006.
PubMed
9) Thune JJ, et al : Effect of antecedent hypertension and follow-up blood pressure on outcomes after highrisk myocardial infarction. Hypertension 51 : 48-54, 2008.
PubMed
10) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265 : 3255-3264, 1991.
 
11) Fagard RH, et al : On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med 167 : 1884-1891, 2007.
PubMed
12) Ogihara T, et al : Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan. Geriatr Gerontol Int 11 : 414-421, 2011.
PubMed
13) Glynn RI, et al : Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 39 : 105-110, 2002.
 
14) Psaty BM, et al : Association betWeen blood pressure level and the risk of myocardial infarction, stroke, and total mortality : the cardiovascular health study. Arch Intern Med 161 : 1183-1192, 2001.
PubMed
15) Lewington S, et al : Age-specific relevance of usual blood pressure to vascular mortality : ameta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 : 1903-1913, 2002.
 
16) Turnbull E et al : Effects of different blood-pressure-lowering regimens on major cardiovascular events : results of prospectively-designed overviews of randomised trials. Lancet 362 : 1527-1535, 2003.
 
17) Ettehad D, et al : Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis. Lancet 387 : 957-967, 2016.
 
18) The SPRINT Research Group : A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373 : 2103-2116, 2015.
 
P.567 掲載の参考文献
1) Masuda M, et al : Thoracic and cardiovascular surgery in Japan during 2013. Annual report by The Japanese Association for Thoracic Surgery, Gen Thorac Cardiovasc Surg 63 : 670-701, 2015.
PubMed
2) Nashef SA, et al : EuroSCORE II. Eur J Cardiothorac Surg 41 : 734-744 ; discussion 744-745, 2012.
 
3) Vaccarino V, et al : Sex differences in hospital mortality after coronary artery bypass surgery : evidence for a higher mortality in younger women. Circulation 105 : 1176-1181, 2002.
PubMed
4) Bukkapatnam RN, et al : Operative mortality in women and men undergoing coronary artery bypass grafting (from the California Coronary Artery Bypass Grafting Outcomes Reporting Program). Am J Cardiol 105 : 339-342, 2010.
PubMed
5) Parolari A, et al : Do women currently receive the same standard of care in coronary artery bypass graft procedures as men? A propensity analysis. Ann Thorac Surg 85 : 885-890, 2008.
 
6) Saxena A, et al : Sex differences in outcomes following isolated coronary artery bypass graft surgery in Australian patients : analysis of the Australasian Society of Cardiac and Thoracic Surgeons cardiac surgery database. Eur J Cardiothorac Surg 41 : 755-762, 2012.
PubMed
7) Puskas JD, et al : ISMICS Consensus Conference and Statements of Randomized Controlled Trials of Off-Pump Versus Conventional Coronary Artery Bypass Surgery. Innovations (Phila) 10 : 219-229, 2015.
PubMed
8) Mack MJ, et al : On-pump versus off-pump coronary artery bypass surgery in a matched sample of women : a comparison of outcomes. Circulation 110 (Suppl II) : II1-6, 2004.
 
9) Mickleborough LL, et al : Gender differences in quality of distal vessels : effect on results of coronary artery bypass grafting. J Thorac Cardiovasc Surg 126 : 950-958, 2003.
PubMed
10) Fukui T, et al : Gender differences in clinical and angiographic outcomes after coronary artery bypass surgery. Circ J 74 : 2103-2108, 2010.
PubMed
11) 循環器領域における性差医療に関するガイドライン. Circ J 74 (Suppl II) : 2010.
 
12) Morris JJ, et al : Gender differences in left ventricular functional response to aortic valve replacement. Circulation 90 : II183-189, 1994.
PubMed
13) Stamou SC, et al : Effects of gender and ethnicity on outcomes after aortic valve replacement. J Thorac Cardiovasc Surg 144 : 486-492, 2012.
PubMed
14) Song HK, et al : Gender differences in mortality after mitral valve operation : evidence for higher mortality in perimenopausal women. Ann Thorac Surg 85 : 2040-2044 ; discussion 2045, 2008.
PubMed
15) Nienaber CA, et al : Gender-related differences in acute aortic dissection. Circulation 109 : 3014-3021, 2004.
PubMed
16) Fukui T, et al : Gender differences in patients undergoing surgery for acute type A aortic dissection. J Thorac Cardiovasc Surg 150 : 581-587. e1, 2015.
 
P.570 掲載の参考文献
1) Kempczinski RF : Vascular conduits : An overview. Rutherford Vascular Surgery, Section VI Chap 33, p527-618.
 
2) Matsumoto H, et al : A new vascular prosthesis for a small caliber artery. Surgery 74 : 519-523, 1973.
PubMed
3) Soyer T, et al : A new venous prosthesis. Surgery 72 : 864-872, 1972.
PubMed
4) Schroeder TV, et al : Dilatation of aortic grafts over time : what to expect and when to be concerned. Semin Vasc Surg 22 : 119-124, 2009.
PubMed
5) Tai NR, et al : Compliance properties of conduits used in vascular reconstruction. Br J Surg 87 : 1516-1524, 2000.
PubMed
6) Salacinski HJ, et al : The mechanical behaVior of vascular grafts : a review. J Biomater Appl 15 : 241-278, 2001.
PubMed
7) Sauvage LR, et al : Successful interposition synthetic graft between aorta and right coronary artery. Angiographic follow-up to siXteen months. J Thorac Cardiovasc Surg 72 : 418-421, 1976.
PubMed
8) Silver GM, et al : Umbilical vein for aortocoronary bypass. Angiology 33 : 450-453, 1982.
PubMed
9) Vrandecic MO : New graft for the surgical treatment of small vessel diseases. J Cardiovasc Surg (Torino) 28 : 711-714, 1987.
PubMed
10) Suma H, et al : Bovine internal thoracic artery graft. Successful use at urgent coronary bypass surgery. J Cardiovasc Surg (Torino) 32 : 268-270, 1991.
PubMed
11) Hoenig MR, et al : Tissue-engineered blood vessels : alternative to autologous grafts? Arterioscler Thromb Vasc Biol 25 : 1128-1134, 2005.
PubMed
12) Shin'oka T et al : Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J Thorac Cardiovasc Surg 129 : 1330-1338, 2005.
PubMed
13) Seifalian AM, et al : In vivo biostability of a poly (carbonate-urea) urethane graft. Biomaterials 24 : 2549-2557, 2003.
PubMed
14) Ishii Y, et al : A novel bioengineered small-caliber vascular graft incorporating heparin and sirolimus : excellent 6-month patency. J Thorac Cardiovasc Surg 135 : 1237-1245 ; discussion 1245-1246, 2008.
 
15) Desai M, et al : Role of prosthetic conduits in coronary artery bypass grafting. Eur J Cardiothorac Surg 40 : 394-398, 2011.
PubMed

書評

最近チェックした商品履歴

Loading...